



PATENT #16
Docket No.: CLV-30880/A/CGV2112

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Martha Martin
Type or print name

Martha Martin
Signature

June 19, 2008
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Hirt, et al

APPLICATION NO: **09/525,158**

FILED: **March 14, 2000**

FOR: **Organic Compounds**

Examiner:

Kuo-Liang Peng

Art Unit: **1712**

RECEIVED

JUN 30 2008

OFFICE OF PETITIONS

Attention: Office of Petitions
Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
FAX (571) 273-8300

Adjustment date: 11/12/2008 CKHL OK
06/26/2008 TL0011 00000001 502965 09525158
01 FC:1453 1540.00 CR

RENEWED PETITION UNDER 37 C.F.R. §1.137(b) AND/OR
RENEWED PETITION TO WITHDRAW THE HOLDING OF ABANDONMENT

Dear Sir:

This is a renewed petition to revive the subject application.

The Decision on Petition on February 20, 2008 from the Office of Petitions dismissed Applicants' petitions to withdraw holding of abandonment and petition under 37 C.F.R. §1.137(b). In response to the dismissal decision, Applicants respectfully request reconsideration of the Applicants' petition in view the Applicants' arguments *infra* and the attached documents supporting the Applicants' arguments. The documents submitted herewith include, copies of four work dockets (redacted) for Jian Zhou and printed on May 1, 2002, August 28, 2002, November 20, 2002, and August 14, 2006 respectively (Appendices A1-A4), Case Docket Report printed out on April 16, 2008 (Appendix B), the copy of the case folder showing all of entries in this case (Appendix C), copies of the redacted minutes of IPSC

06/26/2008 TL0011 00000001 502965 09525158

01 FC:1453 1540.00 DA

(Intellectual Property Steering Committee) meetings mentioning this case CL/V-30880 from 1999 to 2007 (Appendices D1-D13), copies of CL/V-30880 docket records incorporated in IPSC Booklets (Appendices E1-E5), and copies of all of the internal communications found in the case folder (Appendices F1-F20).

PETITION TO WITHDRAW HOLDING OF ABANDONMENT

The Office of Petitions dismissed the Applicants' petition to withdraw holding of abandonment, because no status inquiries were filed during the period from the filing of the original petition to withdraw the holding of abandonment on May 28, 2002 to the filing of the subject petition on September 11, 2007. Applicants respectfully submit that the dismissal is improper because of lack of justification for dismissal for the following reasons.

It is true that MPEP 203.08 states, in pertinent part, that "in the event that a six month period has elapsed, and no response from the Office is received, applicant should inquire as to the status of the application to avoid potential abandonment." (cited by the Petition Office; emphasis in the original) However, the examination of the language in MPEP 203.08 cited by the Petition Office reveals that MPEP 203.08 does not, at all, absolutely mandate/command the applicant to inquire as to the status of the application, because MPEP 203.08 uses the word "should", not "shall" or "must", in the language. Instead, MPEP 203.08 merely recommends or encourages applicants to make status inquiries. Moreover, MPEP 203.08 states, "Applicants are encouraged to use PAIR to make status inquiries" (the sentence following immediately the sentence cited by the Petition Office) [Emphasis added]. This sentence clearly indicates that lack of status inquiry would not constitute a basis for rejecting a timely-filed petition to withdraw holding of abandonment, because status inquiries made on PAIR cannot make evidentiary records and cannot induce the Patent Office to act on the petition. Therefore, without commanding word "shall" or "must", there is no basis to dismiss the applicants' petition so long as the applicants' original petition was timely filed and met the requirements when it was filed.

Applicants respectfully request reconsideration the petition to withdraw holding of abandonment. Alternatively, Applicants request reconsideration of the petition under 37 C.F.R. §1.137(b) for the reasons stated below.

PETITION UNDER 37 CFR §1.137(b)

The Office of Petitions dismissed the Applicants' petition under 37 C.F.R. §1.137(b), because the petition filed on September 14, 2007 lacks a statement that the entire delay in

filing the required reply from the due date for the replay until the filing of a grantable petition pursuant to 37 CFR §1.137(b) was unintentional (Decision, page 4, 6th full paragraph, last sentence). In response, Applicants respectfully request reconsideration in view of the arguments below and documents attached herewith.

First, the entire delay in filing the required reply from the due date for the replay until the filing of a grantable petition pursuant to 37 CFR §1.137(b) was unintentional.

As stated in the petition to withdraw holding of abandonment, Applicants' representative did not receive the Notice of Allowance and the entire delay in paying the required issue fee within the statutory period of three months from the mailing date of the Notice of Allowance was unintentional. The failure to pay the issue fee was discovered on April 25, 2002, when Applicants received the Notice of Abandonment dated April 5, 2002. After having received the Notice of Abandonment dated April 5, 2002, Applicants timely filed the Petition to Withdraw Holding of Abandonment pursuant to 37 C.F.R. §1.181(a), copy of which is attached herewith along with the Return-Receipt Post Card with USPTO stamp of date of May 28, 2002 as well as the petition's supporting documents (a copy (2 pages) of the docket record showing all received Office Actions and replies filed by Applicants' representative; email communication concerning non-receipt of the Notice of Allowance; and a statement of non-receipt of the Notice of Allowance from Jian Zhou, Applicants' representative).

Inadvertently and erroneously, the event of filing Petition to Withdraw Holding of Abandonment was docketed in the database as an event of filing Response to Office Action in the docket for this case (see Appendix B attached herewith, though the entry for this event was correct on the case folder (see the attached Appendix C). Because of this docketing error, the event "status check" did not appear in action dockets to prompt the Applicants' representative to inquire as to the status of the petition since May 10, 2002 (see Appendices A1-A4). Appendix A1 (the action docket prior to filing of petition to withdraw holding of abandonment on May 25, 2002) shows that there was response due for the Applicant's representative on page 77. Appendices A2-A4 show that no action was due for this case in action dockets after the petition to withdraw holding of abandonment was filed on May 25, 2002.

Applicants did not have any intention to abandon this application, but instead, did intend to maintain patents/patent applications for this case in the U.S. and other foreign countries, as supported by the documents attached herewith (Appendices D1-D13 and E1-E5). The copies of the redacted minutes of IPSC (Intellectual Property Steering Committee)

meeting discussing cases including this pending application (Appendices D1-D13) show that since having filed this patent application March 30, 1999, Applicants never wanted to abandon the patent application in the U.S., but instead always decided to maintain the patent application in the U.S. The docket records for this case were incorporated in the IPSC Booklets and the copies thereof (Appendices E1-E5) show that the status of the U.S. patent application for this case was pending.

Applicants did not deliberately choose not to seek or persist in seeking the revival of an abandoned application. As discussed above, Applicants timely filed a petition to withdraw holding of abandonment with all necessary support documents, within one month after Applicants discovered the failure to pay issue fee. The Patent Office acknowledged the receipt of that petition and supporting documents by mailing back to Applicants the Return-Receipt Post Card with US PTO stamp of date of May 28, 2002. The Patent Office further conceded in the Decision on Petition that Applicants did timely file a petition with the documents supporting the petition, because the Patent Office did locate them in the official file. The filing of Applicants' petition to withdraw holding of abandonment was a *bona fide* attempt to revive the application, because the petition was filed timely and met the requirements set forth in MPEP 711.03(c)(I), Subsection A. The petition itself is the best evidence showing the Applicants' intent to revive the patent application. Applicants did not do anything causing the Patent Office not to consider the Applicants' petition during a period of five years. What Applicants failed to do was at most the failure to inquire as to the status of the petition. Such failure was due to the inadvertent docketing error discussed above. However, as discussed above, lack of status inquiry could not constitute any basis for rejecting a timely-filed petition to withdraw holding of abandonment. The inadvertent error in docketing and subsequent failure to inquire as to the status of a timely-filed bona fide petition to withdraw holding of abandonment clearly do not constitute any deliberate action taken by Applicants not to seek or persist in seeking the revival of an abandoned application.

Applicants submit herewith the copies (Appendices F1-F20) of the internal communications which are located in the CLV-30880A case folder. None of the communications can show that Applicants deliberately choose not to seek or persist in seeking the revival of an abandoned application.

In the Q2 2007 IPSC meeting, this case was reviewed again along with many other cases. Applicants' representatives realized that the subject application was pending for too long. Subsequent review of the case folder revealed that Applicants filed a petition to withdraw holding of abandonment on May 10, 2002, but had not received any decision. Applicants

decided to submit the petition to revive the subject application in accordance with 37 C.F.R. §1.137(b), in order to expedite the petition process and issuance of the subject application. On September 11, 2007, Applicants filed the petition which was dismissed by the Petition Office on February 20, 2008.

Therefore, when considering all of the circumstances surrounding the subject application, the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR §1.137(b) was unintentional.

Second, the facts here are materially distinguishable from the facts in each of the case law authorities cited by the Petition Office to support its decision to dismiss the Applicants' petition to revive the subject application in accordance with 37 C.F.R. §1.137(b) as follows.

In *Lawman Armor v. Simon*, 2005 U.S. Dist. LEXIS 10843, 74 U.S.P.Q.2d 1633 (E. D. Mich. 2005), the court found that the defendant had made a decision not to pursue the prosecution of his patent application, because the defendant failed to respond to his representative's two requests for instruction regarding filing a response to final Office Action and to pay his representative's service rendered for prosecuting his patent application, and because the defendant "regained interest in his by then abandoned patent application" after about two years when he discovered the allegedly infringing product at Sears. The court ruled that "these were deliberate acts, and cannot be considered unintentional." In contrast to the defendant in the *Lawman* case, Applicants here did not take deliberate acts not to respond to an office action, but instead took affirmative and timely action to seek to respond to an office action by requesting a Notice of Allowance be remailed in the timely-filed petition to withdraw holding of abandonment. Applicants here timely sought to revive the abandoned patent application by timely filing a petition to withdraw holding of abandonment after discovering the failure to pay the issue fee. Here, there was no purposeful delay in seeking revival, unlike in the *Lawman* case.

In *Field Hybrids, LLC v. Toyota Motor Corp.*, 2005 U.S. Dist. LEXIS 1159 (D. Minn. 2005), although the plaintiff knew that his patent application was in danger of being abandoned through his representatives' communications to him, he explicitly requested his representative to "proceed no further with [his patent application] at this point." In contrast to the plaintiff in the *Field Hybrids* case, Applicants here took affirmative and timely action to seek to respond to an office action by requesting a Notice of Allowance be re-mailed in the timely-filed petition to withdraw holding of abandonment. Applicants here timely sought to revive the abandoned patent application by timely filing a petition to withdraw holding of

abandonment after discovering the failure to pay the issue fee. Here, there was no purposeful decision to take no action, unlike in the Field Hybrids case.

In *Lumenyte Int'l Corp. v. Cable Lite Corp.*, Nos. 96-1011, 96-1077, 1996 U.S. App. LEXIS 16400, 1996 WL 383927 (Fed. Cir. 1996), in a letter to Mr. Willford (the president of the plaintiff), Mr. Rozsa (the plaintiff's representative) summarized a prior conversation and stated that "[Mr. Willford] informed me that [he has] decided not to spend additional money prosecuting the above referenced patent application and that it was [his] desire not to respond to the outstanding office action of February 4, 1988. Therefore, I will not do any further work on this application and it will go abandoned on August 4, 1988." Based on this evidence and others in the records, the Lumenyte court found that the plaintiff intentionally abandoned its patent application and was revived only after and because Fiber Lite ("former name of Cable Lite") introduced a competing product. In contrast to the plaintiff in the Lumenyte case, Applicants here never intentionally abandoned the subject patent application, but instead, timely sought to revive the abandoned patent application by timely filing a petition to withdraw holding of abandonment after discovering the failure to pay the issue fee.

In *New York University v. Autodesk*, 2007 U.S. Dist. LEXIS 50832 (S.D.N.Y. 2007), the key facts were: (1) the PTO's records (Examiner Burwell's note) showed that the PTO examiner telephoned NYU's then attorney who confirmed the abandonment; and (2) several months later NYU's new attorney filed a petition to revive the application under 37 C.F.R. §1.137(b) and did not provide any reason or support for the representation that NYU's failure to file a response was unintentional. The court there held that "[i]n light of [examiner Burwell's note], without more, no reasonable factfinder could find that NYU's decision not to take action – and instead to 'delay' seeking revival – for the entire period between July 14, 1997 and November 4, 1998 was 'inintentional' under 37 C.F.R. §1.137(b)(3)." In contrast to the *NYU v. Autodesk* case, Applicants here did not decide not to take action, but instead timely sought to revive the abandoned patent application by timely filing a petition to withdraw holding of abandonment after discovering the failure to pay the issue fee.

Applicants respectfully submit that, because the facts here are materially distinguishable from the facts in each of the case law authorities cited by the Petition of Office to support its decision to dismiss the Applicants' petition to revive the subject application in accordance with 37 C.F.R. §1.137(b), the cited case law is inapplicable to the pending petition.

Applicants hereby request two months of extension of time under 37 C.F.R. §1.136(a) and authorize payment of the extension of time fee of \$460 under 37 C.F.R. §1.17(a)(2) and other necessary fees by debit of their Deposit Account No. 50-2965 in accordance with 37 C.F.R. §1.17(m).


Applicants hereby authorize payment of the issue fee by debit of their Deposit Account 50-2965 without the issue fee authorization form PTOL 85 B, because Applicants have not received the Notice of Allowance and this form. Alternatively, Applicants respectfully request that a new Notice of Allowance with Form PTOL 85B be re-issued so that Applicant can pay the issue fee.

Since this application was filed on or after June 8, 1995, no terminal disclaimer is required.

Applicants respectfully request that this Petition to revive be granted.

Should the Examiner and/or Senior Petitions Attorney believe that a discussion with Applicants' representative would further the prosecution of this application, either is respectfully invited to contact the undersigned. The Commissioner is hereby authorized to charge any other fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 50-2965.

Respectfully submitted,



Jian S. Zhou
Reg. No. 41,422
(678) 415-4691

Date:

June 19, 2008

CIBA Vision Corporation
Patent Department
11460 Johns Creek Parkway
Duluth, GA 30097-1556

May 8, 2002

DOCKET MANAGEMENT SYSTEM
ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

(A1)

~~Copy~~
Zian's

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
		60/292,980	D C	CVC	JZ				
		60/292,971	D C	CVC	JZ				
		60/293,026	D C	CVC	JZ				
		60/294,407	D C	CVC	JZ				
		60/294,512	D C	CVC	JZ				
		60/294,396	D C	CVC	JZ				
		60/294,397	D C	CVC	JZ				
		60/301,260	D C	CVC	JZ				
		60/303,632	D C	CVC	JZ				
		60/305,684	D C	CVC	JZ				
		09/609,493	D C	CVC	JZ				
		60/292,980	D C	CVC	JZ				
		60/292,971	D C	CVC	JZ				

done?

additional selection criteria:

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
						APPLICATION			
		60/293,026		CVC	JZ				11
		60/294,407		CVC	JZ				11
		60/294,512		CVC	JZ				1
		60/294,396		CVC	JZ				11
		60/294,397		CVC	JZ				11
		60/313,967		CVC	JZ				11
		60/292,980		CVC	JZ				1
		60/292,971		CVC	JZ				1
		60/293,026		CVC	JZ				
		60/301,260		CVC	JZ				
		60/294,407		CVC	JZ				

additional selection criteria:

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
		60/294,512		CVC	JZ				
		60/294,396		CVC	JZ				
		60/294,397		CVC	JZ				
		60/303,632		CVC	JZ				
		60/305,684		CVC	JZ				
		60/292,980	EED	CVC	JZ				
		60/292,971	EED	CVC	JZ				
		60/293,026	EED	CVC	JZ				
			N	CVC	JZ				
		60/325,133		CVC	JZ				
		60/325,101		CVC	JZ				
		60/301,260		CVC	JZ				

Done

additional selection criteria:

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
SP done		09/627,807							
		60/294,407							
		60/294,512							
		60/294,396							
		60/294,397							
		60/303,632							
		10/091,819							
		09/725,405							
		60/305,684							
		60/313,967							
		60/292,980							
		60/292,971							

additional selection criteria:

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
		60/293,026		CVC	JZ				
		60/301,260		CVC	JZ				
		60/334,709		CVC	JZ				
		60/294,407		CVC	JZ				
		60/294,512		CVC	JZ				
		60/294,396		CVC	JZ				
		60/294,397		CVC	JZ				
		60/334,854		CVC	JZ				
		<u>10/091,819</u>		CVC	JZ				
		60/303,632		CVC	JZ				
		60/347,995		CVC	JZ				
		60/348,257		CVC	JZ				

additional selection criteria:

7.2

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
				CVC	JZ				
		60/337,763		CVC	JZ				
		60/340,410		CVC	JZ				
		60/364,192		CVC	JZ				
		60/332,289		CVC	JZ				
		60/305,684		CVC	JZ				
		60/313,967		CVC	JZ				2
		60/292,980		CVC	JZ				1
		60/292,980		CVC	JZ				1
		60/292,971		CVC	JZ				1
		60/292,971		CVC	JZ				1

additional selection criteria:

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
01	A	F		CVC	JZ				
01	ROV/CVA	60/293,026		CVC	JZ				
01	ROV/CVA	60/325,133		CVC	JZ				
01	ROV/CVA	60/325,101		CVC	JZ				
01	A			CVC	JZ				
01	ROV/CVA	60/301,260		CVC	JZ				
01	1239	09/286,530		CVC	JZ				
01	ROV/CVA	60/294,407		CVC	JZ				
01	ROV/CVA	60/294,407		CVC	JZ				
01	ROV/CVA	60/294,512		CVC	JZ				
01	ROV/CVA	60/294,512		CVC	JZ				
01	ROV/CVA	60/294,396		CVC	JZ				
01	ROV/CVA	60/294,396		CVC	JZ				

additional selection criteria:

D O C K E T M A N A G E M E N T S Y S T E M

05/01/2002
PAGE 77ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
	A	60/294,397		CVC	JZ				
	A	60/294,397		CVC	JZ				
		09/331,516		CVC	JZ				
06/05/2002	CL/V -30880/A/CGV 2112	09/525,158	RESPONSE	CVC	JZ	NOTICE OF ABANDONMENT	04/05/2002	PENDING	03/14/2000
		60/303,632		CVC	JZ				
		10/091,819		CVC	JZ				
		60/340,806		CVC	JZ				
		60/340,410		CVC	JZ				
		09/558,135		CVC	JZ				
		60/305,684		CVC	JZ				
		60/313,967		CVC	JZ				
		09/367,274		CVC	JZ				
		09/438,684		CVC	JZ				

additional selection criteria:

DOCKET MANAGEMENT SYSTEM

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
	A	60/325,133		CVC	JZ				
	A	60/325,101		CVC	JZ				
	A	60/301,260		E CVC	JZ				
	A	60/301,260		CVC	JZ				
	A	60/334,709		CVC	JZ				
	A	60/334,854		CVC	JZ				
		09/331,516		CVC	JZ				
		60/303,632		3 CVC	JZ				
		60/303,632		CVC	JZ				
		60/347,995		CVC	JZ				
		60/348,257		CVC	JZ				
		60/337,763		CVC	JZ				
		60/347,116		CVC	JZ				

additional selection criteria:

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	PO ACTION	PO DATE	STATUS	STATUS EFFECTIVE DATE
		60/332,289	CK CC		CVC	JZ			
		60/305,684	DE XT	E	CVC	JZ			
		60/305,684	FJ AI		CVC	JZ			
		60/313,967	RJ		CVC	JZ			
		09/367,274	I		CVC	JZ			
		60/325,133	I N		CVC	JZ			
		60/325,101	I N		CVC	JZ			
		60/334,709	I		CVC	JZ			
		60/334,854	I		CVC	JZ			
		60/347,995			CVC	JZ			
		60/348,257			CVC	JZ			
		60/337,763			CVC	JZ			
		60/340,806			CVC	JZ			

additional selection criteria:

ACTION DOCKET from 01/01/1950 to 08/31/2002
SORTED BY DUE DATE FOR ATTORNEY: JZ

ACTION DUE DATE	CASE NUMBER	SERIAL NO. (PATENT NO)	ATTORNEY ACTION DUE	GROUP	RESPONS. ATTORNEY (CASE)	APPLICATION		STATUS	EFFECTIVE DATE
						PO ACTION	PO DATE		

CONVERT?

VA	60/332,289	I		CVC	JZ				
VA	60/340,410	(CVC	JZ				
VA	60/313,967	I	I-E	CVC	JZ				
VA	60/313,967	I		CVC	JZ				
VA	60/325,133	I	SE	CVC	JZ				
VA	60/325,101	I	SE	CVC	JZ				
VA	60/334,709	:	EED	CVC	JZ				
VA	60/334,854	:	EED	CVC	JZ				

additional selection criteria:

Through: 11/30/2002

Printed: 08/28/2002

ATTORNEY #1 DOCKET FOR JIAN ZHOU

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
September 1998								
24 Thu	JZ/RJG/RIG			RE CIBA Vision Corporation	(US) N/A		0	None
March 1999								
24 Wed	JZ/RJG/RIG			RE CIBA Vision Corporation	(US) N/A		0	None
November 2000								
12 Sun	JZ/RJG/RIG			CIBA Vision Corporation	(US) 10/197,036		0	None
January 2001								
09 Tue	JZ/RJG/RIG			3 C CIBA Vision Corporation	(US) 09/710,514		0	None
March 2001								
22 Thu	JZ/RJG/RIG			MA CIBA Vision Corporation	(US) 09/766,725		0	None
April 2001								
15 Sun	JZ/RJG/RIG			CIBA Vision Corporation	(US) 09/784,471		0	None
May 2001								
05 Sat	JZ/RJG/RIG			IN CIBA Vision Corporation	(US)			None
16 Wed	JZ/RJG/RIG			ITA CIBA Vision Corporation	(US) 09/811,023			None
19 Sat	JZ/RJG/RIG			CIBA Vision Corporation	(US) 09/444,480			None
June 2001								
25 Mon	JZ/RJG/RIG			L CIBA Vision Corporation	(US) 09/775,104			None
July 2001								
16 Mon	JZ/RJG/RIG			CIBA Vision Corporation	(US) 09/858,394			None

A2

Through: 11/30/2002

DATE	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
	ATTY1/ATTY2						
	BABA						

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
August 2001								
04 Sat	JZ/RJG/RIG				(US) 09/873,827			
12 Sun	JZ/RJG/RIG				(US) 09/879,013			
September 2001								
06 Thu	JZ/RJG/RIG				(US) 09/901,886			
23 Sun	JZ/RJG/RIG				(US) 09/911,221			
23 Sun	JZ/RJG/RIG				(US) 09/911,330			
23 Sun	JZ/RJG/RIG				(US) 09/911,332			
23 Sun	JZ/RJG/RIG				(US) 09/911,218			
October 2001								
02 Tue	JZ/RJG/RIG				(US) 09/920,690			
14 Sun	JZ/RJG/RIG				(US) 09/929,396			
24 Wed	JZ/RJG/RIG				(US) 09/939,145			
29 Mon	JZ/RJG/RIG				(US) 09/941,818			
November 2001								
02 Fri	JZ/RJG/RIG				(US) 09/442,397			
January 2002								
16 Wed	JZ/RJG/RIG				(US) 09/981,391			
18 Fri	JZ/RJG/RIG				(US) 09/559,945			
22 Tue	JZ/RJG/RIG				(US) 10/047,042			
February 2002								

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT	AVAILABLE
<i>February continued...</i>									
04 Mon	JZ/RJG/RIG				(US) 09/755,443				
March 2002									
20 Wed	JZ/RJG/RIG				(US) 10/019,134				
April 2002									
04 Thu	JZ/RJG/RIG				(US) 09/873,827				
24 Wed	JZ/RJG/RIG				(US) 10/056,694				
24 Wed	JZ/RJG/RIG				(US) 10/056,168				
June 2002									
06 Thu	JZ/RJG/RIG				(US) 10/091,819				
13 Thu	JZ/RJG/RIG				(US) 09/698,544				
26 Wed	JZ/RJG/RIG				(US) 09/893,148				
July 2002									
03 Wed	JZ/RJG/RIG				(US) 10/115,401				
14 Sun	JZ/RJG/RIG				(US) 60/332,289				
21 Sun	JZ/RJG/RIG				(US) 60/313,898				
22 Mon	JZ/RJG/RIG				(US) 10/127,736				
29 Mon	JZ/RJG/RIG				(US) 10/106,739				
29 Mon	JZ/RJG/RIG				(US) 09/879,013				
31 Wed	JZ/RJG/RIG				(US) 09/774,942				

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT
DUE	PARA						EXT	AVAILABLE	
August 2002									
07 Wed	JZ/RJG/RIG				(US) N/A				
09 Fri	JZ/RJG/RIG				(US) 10/141,746				
09 Fri	JZ/RJG/RIG				(US) 10/142,300				
09 Fri	JZ/RJG/RIG				(US) 60/371,561				
14 Wed	JZ/RJG/RIG				(US) 60/332,289				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
22 Thu	JZ/RJG/RIG				(US) 10/153,047				
22 Thu	JZ/RJG/RIG				(US) 10/152,941				
22 Thu	JZ/RJG/RIG				(US) 10/153,037				
22 Thu	JZ/RJG/RIG				(US) 10/154,249				
22 Thu	JZ/RJG/RIG				(US) 10/153,040				
22 Thu	JZ/RJG/RIG				(US) 10/153,007				
22 Thu	JZ/RJG/RIG				(US) 10/153,063				
24 Sat	JZ/RJG/RIG				(US) 09/939,145				
26 Mon	JZ/RJG/RIG				(US) 09/893,148				
September 2002									
05 Thu	JZ/RJG/RIG				(US) 10/154,249				

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT	AVAILABLE
<i>September continued...</i>									
06 Fri	JZ/RJG/RIG				(US) 09/559,945				a
07 Sat	JZ/RJG/RIG				(US) N/A				a
11 Wed	JZ/RJG/RIG				(US) 09/755,357				h
14 Sat	JZ/RJG/RIG				(US) 60/332,289				a
15 Sun	JZ/RJG/RIG				(US) 08/274,942				a
16 Mon	JZ/RJG/RIG				(US) 09/811,023				a
19 Thu	JZ/RJG/RIG				(US) 10/153,007				h
20 Fri	JZ/RJG/RIG				(US) 09/508,785				e
20 Fri	JZ/RJG/RIG				(US) 10/175,656				e
20 Fri	JZ/RJG/RIG				(US) 09/725,405				e
21 Sat	JZ/RJG/RIG				(US) 09/714,691				e
21 Sat	JZ/RJG/RIG				(US) N/A				e
26 Thu	JZ/RJG/RIG				(US) 08/274,942				e
27 Fri	JZ/RJG/RIG				(US) 10/153,063				h
October 2002									
02 Wed	JZ/RJG/RIG				(US) 09/530,073				h
03 Thu	JZ/RJG/RIG				(US) 10/190,415				e
03 Thu	JZ/RJG/RIG				(US) 09/784,471				h
04 Fri	JZ/RJG/RIG				(US) 09/939,145				e

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT	AVAILABLE
<i>October continued...</i>									
07 Mon	JZ/RJG/RIG				(US) N/A				e
08 Tue	JZ/RJG/RIG				(US) 10/091,820				e
09 Wed	JZ/RJG/RIG				(US) 10/191,613				e
12 Sat	JZ/RJG/RIG				(US) 10/191,613				h
14 Mon	JZ/RJG/RIG				(US) 60/332,289				e
19 Sat	JZ/RJG/RIG				(US) 09/838,439				e
23 Wed	JZ/RJG/RIG				(US) 09/586,859				e
23 Wed	JZ/RJG/RIG				(US) 09/438,684				e
31 Thu	JZ/RJG/RIG				(US) N/A				e
November 2002									
02 Sat	JZ/RJG/RIG				(US) 09/409,759				e
07 Thu	JZ/RJG/RIG				(US) 60/347,995				e
07 Thu	JZ/RJG/RIG				(US) 60/347,995				e
07 Thu	JZ/RJG/RIG				(US) 60/347,995				e
07 Thu	JZ/RJG/RIG				(US) 60/347,995				e
07 Thu	JZ/RJG/RIG				(US) N/A				e
07 Thu	JZ/RJG/RIG				(US) N/A				e
07 Thu	JZ/RJG/RIG				(US) N/A				e

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	AVAILABLE
DUE	PARA						EXT	EXT		
November continued...										
07 Thu	JZ/RJG/RIG				(US) N/A	C				
07 Thu	JZ/RJG/RIG				(US) N/A	F				
07 Thu	JZ/RJG/RIG				(US) N/A	F				
07 Thu	JZ/RJG/RIG				(US) N/A	I				
12 Tue	JZ/RJG/RIG				(US) 09/645,900	F				
14 Thu	JZ/RJG/RIG				(US) 09/811,023	I				
14 Thu	JZ/RJG/RIG				(US) 60/332,289	F				
14 Thu	JZ/RJG/RIG				(US) 60/332,289	F				
14 Thu	JZ/RJG/RIG				(US) 60/332,289	I				
16 Sat	JZ/RJG/RIG				(US) 09/858,394	I				
21 Thu	JZ/RJG/RIG				(US) N/A	I				
30 Sat	JZ/RJG/RIG				(US) 09/867,827	I				
<hr/>										
* docket will always print advanced ca										
<hr/>										
December 2002										
04 Wed	JZ/RJG/RIG				(US) 09/873,827	I				
12 Thu	JZ/RJG/RIG				(US) 09/879,013	I				
14 Sat	JZ/RJG/RIG				(US) 60/340,410	I				
14 Sat	JZ/RJG/RIG				(US) 60/340,410					
20 Fri	JZ/RJG/RIG				(US) 10/019,134					

docket will always print advanced c

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/30/2002

Printed: 08/28/2002

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
<i>December continued...</i>								
26 Thu	JZ/RJG/RIG				(US) 09/893,148	I		one
26 Thu	JZ/RJG/RIG				(US) 09/893,148	I		one
<i>January 2003</i>								
09 Thu	JZ/RJG/RIG				(US) 60/347,116	F		ne
09 Thu	JZ/RJG/RIG				(US) 60/347,116	F		ne
24 Fri	JZ/RJG/RIG				(US) 10/056,694	F		ne
24 Fri	JZ/RJG/RIG				(US) 10/056,168	F		ne
<i>February 2003</i>								
14 Fri	JZ/RJG/RIG				(US) 60/356,954	F		ne
14 Fri	JZ/RJG/RIG				(US) 60/356,954	F		ne
TOTAL ITEMS SELECTED =							119	

Best Available Copy

A3

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
September 1998								
24 Thu	JZ/RJG/RIG				(US) 10/225,062	F		ne
March 1999								
24 Wed	JZ/RJG/RIG				(US) 10/225,062	P		ne
November 2000								
12 Sun	JZ/RJG/RIG				(US) 10/197,036	F		ne
January 2001								
09 Tue	JZ/RJG/RIG				(US) 09/710,514	P		ne
March 2001								
07 Wed	JZ/RJG/RIG				(US) 09/731,331	IF		ne
22 Thu	JZ/RJG/RIG				(US) 09/766,725	P		ne
April 2001								
15 Sun	JZ/RJG/RIG				(US) 09/784,471	P		ne
16 Mon	JZ/RJG/RIG				(US) 09/811,023	R		ne
May 2001								
05 Sat	JZ/RJG/RIG				(US)	F		ne
16 Wed	JZ/RJG/RIG				(US) 09/811,023	P		ne
19 Sat	JZ/RJG/RIG				(US) 09/444,480	S		ne
20 Sun	JZ/RJG/RIG				(US) 6,440,411	R		ne
July 2001								

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT		AVAILABLE
DUE	PARA						EXT	EXT			
July continued...											
16 Mon	JZ/RJG/RIG				(US) 09/858,394						
August 2001											
02 Thu	JZ/RJG/RIG				(US) 09/920,690						
04 Sat	JZ/RJG/RIG				(US) 09/873,827						
12 Sun	JZ/RJG/RIG				(US) 09/879,013						
September 2001											
06 Thu	JZ/RJG/RIG				(US) 09/901,886						
10 Mon	JZ/RJG/RIG				(US) 09/920,690						
23 Sun	JZ/RJG/RIG				(US) 09/911,221						
23 Sun	JZ/RJG/RIG				(US) 09/911,330						
23 Sun	JZ/RJG/RIG				(US) 09/911,332						
23 Sun	JZ/RJG/RIG				(US) 09/911,218						
October 2001											
02 Tue	JZ/RJG/RIG				(US) 09/920,690						
14 Sun	JZ/RJG/RIG				(US) 09/929,396						
24 Wed	JZ/RJG/RIG				(US) 09/939,145						
29 Mon	JZ/RJG/RIG				(US) 09/941,818						
December 2001											
07 Fri	JZ/RJG/RIG				(US) 09/731,331						
January 2002											

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
<i>January continued...</i>								
16 Wed	JZ/RJG/RIG				(US) 09/981,391			
February 2002								
04 Mon	JZ/RJG/RIG				(US) 09/755,443			
07 Thu	JZ/RJG/RIG				(US) 09/731,331			
March 2002								
20 Wed	JZ/RJG/RIG				(US) 10/019,134			
April 2002								
04 Thu	JZ/RJG/RIG				(US) 09/873,827			
24 Wed	JZ/RJG/RIG				(US) 10/056,694			
24 Wed	JZ/RJG/RIG				(US) 10/056,168			
June 2002								
06 Thu	JZ/RJG/RIG				(US) 10/091,819			
07 Fri	JZ/RJG/RIG				(US) 09/731,331			
07 Fri	JZ/RJG/RIG				(US) 09/731,331			
26 Wed	JZ/RJG/RIG				(JS) 09/893,148			
26 Wed	JZ/RJG/RIG				(JS) 10/106,751			
July 2002								
03 Wed	JZ/RJG/RIG				(JS) 10/115,401			
14 Sun	JZ/RJG/RIG				(JS) 60/332,289			
21 Sun	JZ/RJG/RIG				(JS) 60/313,898			

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

DUE	ATTY/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT	AVAILABLE
<i>July continued...</i>									
22 Mon	JZ/RJG/RIG				(US) 10/127,736				
29 Mon	JZ/RJG/RIG				(US) 10/197,036				
29 Mon	JZ/RJG/RIG				(US) 10/106,739				
31 Wed	JZ/RJG/RIG				(US) 09/774,942				
<i>August 2002</i>									
07 Wed	JZ/RJG/RIG				(US) N/A				
09 Fri	JZ/RJG/RIG				(US) 10/142,300				
09 Fri	JZ/RJG/RIG				(US) 60/371,561				
14 Wed	JZ/RJG/RIG				(US) 60/332,289				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
21 Wed	JZ/RJG/RIG				(US) 60/313,898				
22 Thu	JZ/RJG/RIG				(US) 10/153,047				
22 Thu	JZ/RJG/RIG				(US) 10/152,941				
22 Thu	JZ/RJG/RIG				(US) 10/153,037				
22 Thu	JZ/RJG/RIG				(US) 10/154,249				
22 Thu	JZ/RJG/RIG				(US) 10/153,040				
22 Thu	JZ/RJG/RIG				(US) 10/153,007				
22 Thu	JZ/RJG/RIG				(US) 10/153,063				
24 Sat	JZ/RJG/RIG				(US) 09/939,145				
26 Mon	JZ/RJG/RIG				(US) 09/893,148				

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
September 2002								
06 Fri	JZ/RJG/RIG				(US) 6,451,871			
07 Sat	JZ/RJG/RIG				(US) N/A			
14 Sat	JZ/RJG/RIG				(US) 60/332,289			
16 Mon	JZ/RJG/RIG				(US) 09/811,023			
20 Fri	JZ/RJG/RIG				(US) 10/175,656			
21 Sat	JZ/RJG/RIG				(US) 10/225,062			
October 2002								
04 Fri	JZ/RJG/RIG				(US) 09/939,145			
06 Sun	JZ/RJG/RIG				(US) 60/408,714			
07 Mon	JZ/RJG/RIG				(US) N/A			
08 Tue	JZ/RJG/RIG				(US) 10/091,820			
14 Mon	JZ/RJG/RIG				(US) 60/332,289			
19 Sat	JZ/RJG/RIG				(US) 6,440,411			
23 Wed	JZ/RJG/RIG				(US) 09/586,859			
23 Wed	JZ/RJG/RIG				(US) 09/438,684			
24 Thu	JZ/RJG/RIG				(US) 10/202,758			
31 Thu	JZ/RJG/RIG				(US) N/A			
November 2002								
07 Thu	JZ/RJG/RIG				(US) 60/347,995			
07 Thu	JZ/RJG/RIG				(US) 60/347,995			

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
November continued...								
07 Thu	JZ/RJG/RIG				(US) 60/347,995			
07 Thu	JZ/RJG/RIG				(US) 60/347,995			
07 Thu	JZ/RJG/RIG				(US) N/A			
07 Thu	JZ/RJG/RIG				(US) N/A			
07 Thu	JZ/RJG/RIG				(US) N/A			
07 Thu	JZ/RJG/RIG				(US) N/A			
07 Thu	JZ/RJG/RIG				(US) N/A			
07 Thu	JZ/RJG/RIG				(US) N/A			
07 Thu	JZ/RJG/RIG				(US) N/A			
07 Thu	JZ/RJG/RIG				(US) 10/213,972			
07 Thu	JZ/RJG/RIG				(US) N/A			
11 Mon	JZ/RJG/RIG				(US) 10/269,394			
14 Thu	JZ/RJG/RIG				(US) 60/332,289			
14 Thu	JZ/RJG/RIG				(US) 60/332,289			
14 Thu	JZ/RJG/RIG				(US) 60/332,289			
16 Sat	JZ/RJG/RIG				(US) 09/858,394			
21 Thu	JZ/RJG/RIG				(US) 10/225,062			
26 Tue	JZ/RJG/RIG				(US) 10/115,401			
28 Thu	JZ/RJG/RIG				(US) 09/697,859			
29 Fri	JZ/RJG/RIG				(US) 09/710,514			
30 Sat	JZ/RJG/RIG				(US) 09/867,827			

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	STATUS CHECK	CURRENT EXT	EXT. AVAILABLE
DUE	PARA								
December 2002									
04 Wed	JZ/RJG/RIG				(US) 09/873,827			0	None
05 Thu	JZ/RJG/RIG				(US) 10/153,040				one
06 Fri	JZ/RJG/RIG				(US) 09/586,859				nth
11 Wed	JZ/RJG/RIG				(US) 09/755,357				one
12 Thu	JZ/RJG/RIG				(US) 09/901,886				nth
12 Thu	JZ/RJG/RIG				(US) 09/879,013				one
13 Fri	JZ/RJG/RIG				(US) 09/766,725				nth
14 Sat	JZ/RJG/RIG				(US) 60/340,410				one
19 Thu	JZ/RJG/RIG				(US) 09/697,861				one
20 Fri	JZ/RJG/RIG				(US) 10/019,134				one
21 Sat	JZ/RJG/RIG				(US) 09/911,218				nth
24 Tue	JZ/RJG/RIG				(US) 09/873,827				nth
26 Thu	JZ/RJG/RIG				(US) 09/893,148				one
26 Thu	JZ/RJG/RIG				(US) 09/893,148				one
30 Mon	JZ/RIG/RJG				(US) 09/698,528				one

CALL-UP DATES

The following items are due beyond the current print through date of 12/31/2002. A "regular" docket will always print advanced call-ups.

January 2003

01 Wed	JZ/RJG/RIG	(US) 09/731,331	F	nth
03 Fri	JZ/RJG/RIG	(US) 09/558,135	F	th
04 Sat	JZ/RJG/RIG	(US) 09/755,357	F	th
06 Mon	JZ/RJG/RIG	(US) 09/901,886	S	e

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

Best Available Copy

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
<i>January continued...</i>								
09 Thu	JZ/RJG/RIG				(US) 10/267,377			
09 Thu	JZ/RJG/RIG				(US) 60/347,116			
09 Thu	JZ/RJG/RIG				(US) 60/347,116			
23 Thu	JZ/RJG/RIG				(US) 09/911,221			
23 Thu	JZ/RJG/RIG				(US) 09/911,330			
23 Thu	JZ/RJG/RIG				(US) 09/911,332			
23 Thu	JZ/RJG/RIG				(US) 09/911,218			
24 Fri	JZ/RJG/RIG				(US) 10/056,694			
24 Fri	JZ/RJG/RIG				(US) 10/056,168			
28 Tue	JZ/RJG/RIG				(US) 09/867,827			
30 Thu	JZ/RJG/RIG				(US) N/A			
February 2003								
14 Fri	JZ/RJG/RIG				(US) 60/356,954			
14 Fri	JZ/RJG/RIG				(US) 60/356,954			
14 Fri	JZ/RJG/RIG				(US) 60/356,954			
14 Fri	JZ/RJG/RIG				(US) 60/356,954			
March 2003								
06 Thu	JZ/RJG/RIG				(US) 10/091,820			
06 Thu	JZ/RJG/RIG				(US) 10/091,819			
13 Thu	JZ/RJG/RIG				(US) 60/364,192			
26 Wed	JZ/RJG/RIG				(US) 10/106,751			

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 12/31/2002

Printed: 11/20/2002

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	
							EXT		EXT	AVAILABLE

END OF REPORT

TOTAL ITEMS SELECTED = 139

Best Available Copy

ATTORNEY #1 DOCKET FOR JIAN ZHOU

A4

Through: 11/14/2006

Printed: 8/14/2006

ATTY1/ATTY2		REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT		EXT	
DUE	PARA						EXT	AVAILABLE		
March 2002										
23 Sat	JZ/RJG/RJG				JS) 11/385,418					
23 Sat	JZ/RJG/RJG				JS) N/A					
September 2002										
23 Mon	JZ/RJG/RJG				JS) 11/385,418					
23 Mon	JZ/RJG/RJG				JS) N/A					
October 2002										
24 Thu	JZ/RJG/RJG				JS) 11/443,731					
April 2003										
24 Thu	JZ/RJG/RJG				JS) 11/443,731					
April 2004										
16 Fri	JZ/RJG/RJG				JS) 11/406,108					
August 2004										
20 Fri	JZ/RJG/RJG				JS) N/A					
October 2004										
16 Sat	JZ/RJG/RJG				US) 11/406,108					
January 2005										
10 Mon	JZ/RJG/RJG				US) 10/738,921					
20 Thu	JZ/RJG/RJG				US) 10/969,280					
February 2005										

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
February continued...								
20 Sun	JZ/RJG/RJG				(US) N/A			
March 2005								
08 Tue	JZ/RJG/RJG				(US) 11/007,442			
10 Thu	JZ/RJG/RJG				(WO) PCT/US03/18135			
15 Tue	JZ/RJG/RJG				(US) 11/012,658			
April 2005								
05 Tue	JZ/RJG/RJG				(US) 11/029,619			
19 Tue	JZ/RJG/RJG				(US) 10/522,443			
July 2005								
12 Tue	JZ/RJG/RJG				(US) 11/012,658			
12 Tue	JZ/RJG/RJG				(US) 10/980,589			
26 Tue	JZ/RJG/RJG				(US) 10/991,124			
28 Thu	JZ/RJG/JZ				(US) 60/591,704			
28 Thu	JZ/RJG/JZ				(US) 60/591,704			
August 2005								
23 Tue	JZ/RJG/RJG				(US) 10/736,994			
25 Thu	JZ/RJG/RJG				(US) 11/137,195			
25 Thu	JZ/RJG/RJG				(US) 11/137,181			
30 Tue	JZ/RJG/KAB				(US) 11/148,104			
30 Tue	JZ/RJG/KAB				(US) 11/147,594			

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
September 2005								
01 Thu	JZ/RJG/KAB				(US) 11/216,366			
14 Wed	JZ/RJG/RJG				(US) 11/076,391			
29 Thu	JZ/RJG/KAB				(US) 11/226,725			
October 2005								
04 Tue	JZ/RJG/KAB				(US) 11/196,908			
13 Thu	JZ/RJG/KAB				(US) 11/243,930			
13 Thu	JZ/RJG/KAB				(US) 60/618,157			
18 Tue	JZ/RJG/RJG				(US) 6,955,832			
21 Fri	JZ/RJG/RJG				(US) 11/110,059			
November 2005								
01 Tue	JZ/RJG/KAB				(US) 11/216,366			
04 Fri	JZ/RJG/KAB				(US) 11/196,908			
05 Sat	JZ/RJG/RJG				(US) 11/243,928			
10 Thu	JZ/RJG/RJG				(WO) PCT/US03/18135			
12 Sat	JZ/RJG/JZ				(US) 11/248,548			
13 Sun	JZ/RJG/KAB				(US) 60/618,157			
22 Tue	JZ/RJG/KAB				(US) 11/284,753			
22 Tue	JZ/RJG/JZ				(US) 11/284,747			
29 Tue	JZ/RJG/KAB				(US) 11/226,725			
30 Wed	JZ/RJG/KAB				(US) 11/216,366			

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
November continued...								
30 Wed	JZ/RJG/KAB				(US) 11/226,604			
December 2005								
06 Tue	JZ/RJG/RJG				(US) 11/137,195			
06 Tue	JZ/RJG/RJG				(US) 11/137,181			
06 Tue	JZ/RJG/RJG				(US) 11/093,819			
09 Fri	JZ/RJG/RJG				(US) 10/864,043			
13 Tue	JZ/RJG/KAB				(US) 11/243,930			
15 Thu	JZ/RJG/RJG				(US) 10/736,994			
17 Sat	JZ/RJG/KAB				(US) 11/305,692			
27 Tue	JZ/RJG/RJG				(US) 11/110,059			
January 2006								
05 Thu	JZ/RJG/RJG				(US) 11/243,928			
10 Tue	JZ/RJG/RJG				(WO) PCT/US03/1813			
22 Sun	JZ/RJG/KAB				(US) 11/284,753			
22 Sun	JZ/RJG/JZ				(US) 11/284,747			
26 Thu	JZ/RJG/RJG				(US) 10/554,652			
28 Sat	JZ/RJG/JZ				(US) 11/248,548			
February 2006								
07 Tue	JZ/RJG/RJG				(US) 6,995,192			
11 Sat	JZ/RJG/RJG				(US) 11/329,697			
17 Fri	JZ/RJG/KAB				(US) 11/305,692			

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
<i>February continued...</i>								
21 Tue	JZ/RJG/KAB	CL			(US) 11/284,753	orporation		
21 Tue	JZ/RJG/JZ	CL			(US) 11/284,747	orporation		
28 Tue	JZ/RJG/RJG	CL			(US) 7,004,585	orporation		
March 2006								
04 Sat	JZ/RJG/KAB	CL			(US) 11/365,546	orporation		
05 Sun	JZ/RJG/KAB	CL			(US) 11/148,104	orporation		
05 Sun	JZ/RJG/KAB	CL			(US) 11/147,594	orporation		
09 Thu	JZ/RJG/KAB	CL			(US) 11/365,384	orporation		
16 Thu	JZ/RJG/KAB	CL			(US) 11/305,692	orporation		
19 Sun	JZ/RJG/RJG	CL			(US) 10/470,651	orporation		
April 2006								
04 Tue	JZ/RJG/KAB	CL			(US) 60/658,930	orporation		
04 Tue	JZ/RJG/RJG	LP			(US) 7,022,654	orporation		
09 Sun	JZ/RJG/RJG	CL			(US) 11/243,928	orporation		
11 Tue	JZ/RJG/RJG	CL			(US) 11/329,697	orporation		
20 Thu	JZ/RJG/RJG	LP			(US) 10/969,255	orporation		
21 Fri	JZ/RJG/RJG	CL			(US) 11/385,418	orporation		
May 2006								
04 Thu	JZ/RJG/KAB	CL			(US) 11/365,546	orporation		
04 Thu	JZ/RJG/KAB	CL			(US) 11/415,938	orporation		
05 Fri	JZ/RJG/KAB	CL			(US) 60/677,964	orporation		

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
<i>May continued...</i>								
09 Tue	JZ/RJG/RJG	C		Corporation	(US) 7,040,756			
09 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/365,384			
16 Tue	JZ/RJG/RJG	C		Corporation	(US) 10/522,443			
16 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/196,908			
16 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/216,366			
18 Thu	JZ/RJG/RJG	C		Corporation	(US) 6,737,661			
18 Thu	JZ/RJG/RJG	C		Corporation	(US) 11/406,108			
22 Mon	JZ/RJG/KAB	C		Corporation	(US) 11/284,753			
22 Mon	JZ/RJG/JZ	C		Corporation	(US) 11/284,747			
30 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/226,725			
June 2006								
01 Thu	JZ/RJG/KAB	C		Corporation	(US) 11/365,384			
13 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/226,604			
13 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/243,930			
17 Sat	JZ/RJG/KAB	C		Corporation	(US) 11/305,692			
21 Wed	JZ/RJG/RJG	C		Corporation	(US) 11/385,418			
30 Fri	JZ/RJG/RJG	C		Corporation	(US) 11/443,731			
30 Fri	JZ/RJG/RJG	C		Corporation	(US) N/A			
July 2006								
04 Tue	JZ/RJG/KAB	C		Corporation	(US) 11/415,938			
14 Fri	JZ/RJG/RJG	C		Corporation	(US) N/A			

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
<i>July continued...</i>								
18 Tue	JZ/RJG/RJG	CL			(US) 11/406,108	poration		
27 Thu	JZ/RJG/RJG	CL			(US) 11/093,820	poration		
27 Thu	JZ/RJG/RJG	CL			(US) 11/412,650	poration		
August 2006								
01 Tue	JZ/RJG/RJG	CL			(US) 11/329,697	poration		
10 Thu	JZ/RJG/RJG	CL			(US) N/A	poration		
12 Sat	JZ/RJG/RJG	CL			(US) 10/797,707	poration		
12 Sat	JZ/RJG/RJG	CL			(US) N/A	poration		
23 Wed	JZ/RJG/RJG	CL			(US) 11/065,145	poration		
30 Wed	JZ/RJG/KAB	CL			(US) 60/636,930	poration		
31 Thu	JZ/RJG/RJG	CL			(US) 11/443,731	poration		
31 Thu	JZ/RJG/RJG	LPA			(US) 60/712,862	poration		
31 Thu	JZ/RJG/RJG	LPA			(US) 60/712,862	poration		
September 2006								
01 Fri	JZ/RJG/RJG	CL			(US) 10/476,030	poration		
03 Sun	JZ/RJG/RJG	CL			(US) 10/287,730	poration		
04 Mon	JZ/RJG/KAB	CL			(US) 11/365,546	poration		
09 Sat	JZ/RJG/KAB	CL			(US) 11/365,384	poration		
14 Thu	JZ/RJG/RJG	CL			(US) N/A	poration		
21 Thu	JZ/RJG/RJG	CL			(US) 6,793,973	poration		
22 Fri	JZ/RJG/RJG	CL			(US) 10/676,173	poration		

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
<i>September continued...</i>								
23 Sat	JZ/RJG/RJG	CLV-		: CIBA Vision Corporation	(US) 11/088,089			
23 Sat	JZ/RJG/RJG	CLV-		: CIBA Vision Corporation	(US) 11/416,260			
23 Sat	JZ/RJG/RJG	CLV-		: CIBA Vision Corporation	(US) 60/719,878			
27 Wed	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 10/654,196			
28 Thu	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 11/007,442			
30 Sat	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 10/706,208			
30 Sat	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 11/093,820			
30 Sat	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 11/093,819			
October 2006								
05 Thu	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 6,800,225			
07 Sat	JZ/RJG/KAB	CLV-		CIBA Vision Corporation	(US) 10/654,114			
10 Tue	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) N/A			
12 Thu	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) N/A			
14 Sat	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 10/937,140			
26 Thu	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 6,808,262			
26 Thu	JZ/RJG/RJG	CLV-		CIBA Vision Corporation	(US) 10/554,652			
November 2006								
02 Thu	JZ/RJG/RJG	CLV-		IBA Vision Corporation	(US) 6,811,805			
02 Thu	JZ/RJG/RJG	CLV-		IBA Vision Corporation	(US) 6,811,259			
04 Sat	JZ/RJG/KAB	CLV-		IBA Vision Corporation	(US) 11/415,938			


CALL-UP DATES The following items are due beyond the current print through date of 11/14/2006. A "regular" docket will always print advanced call-ups.

ATTORNEY #1 DOCKET FOR JIAN ZHOU

Through: 11/14/2006

Printed: 8/14/2006

DUE	ATTY1/ATTY2 PARA	REFERENCE#	TITLE / MARK	CLIENT	REG/SERIAL#	ACTION	CURRENT EXT	EXT AVAILABLE
November 2006								
16 Thu	JZ/RJG/RJG	LP			(US) 60/737,206	ation		
16 Thu	JZ/RJG/RJG	LP			(US) 60/737,206	ation		
16 Thu	JZ/RJG/RJG	LP			(US) 60/737,215	ation		
16 Thu	JZ/RJG/RJG	LP			(US) 60/737,215	ation		
16 Thu	JZ/RJG/RJG	LP			(US) 60/737,148	ation		
16 Thu	JZ/RJG/RJG	LP			(US) 60/737,148	ation		
23 Thu	JZ/RJG/RJG	CL			(US) 6,821,108	ation		
23 Thu	JZ/RJG/RJG	CL			(US) 11/416,260	ation		
December 2006								
07 Thu	JZ/RJG/RJG	CL			(US) 6,827,966	ation		
14 Thu	JZ/RJG/RJG	CL			(US) 60/750,195	ation		
14 Thu	JZ/RJG/RJG	CL			(US) 60/750,195	ation		
28 Thu	JZ/RJG/RJG	CL			(US) 6,835,410	ation		
February 2007								
01 Thu	JZ/RJG/RJG	CL			(US) 6,849,210	ation		
END OF REPORT								
TOTAL ITEMS SELECTED =							150	



Home | Setup | Help | Contact Us | Logout

Connected: Martha Martin

Patent Design General Matters Reports Tools

Patent Family Patent Application Third Party Patent Conflict Product

Patent Update

Cancel | Save

Internal Title	ORGANIC COMPOUNDS
Case Reference	CL/V -30880A/CGV US-NP
Family Number	30880
Country	United States Of America
Filing Type	National Patent
Prosecution Step	Pending
Legal Status	
First Filing	United States Of America (NP) - 30 Mar 1999 - 09/280510
First Priority	United States Of America (NP) - 30 Mar 1999 - 09/280510

Live	
<input type="checkbox"/> Critical Dates	
Filing	14 Mar 2000 09/525158
Publication	
Grant	
Abandon	
Expiration	14 Mar 2020
Next Annuity	
Current Status	14 Mar 2000 Filed

Selection




























Filter on

All

☐ Include Annuities and Taxes

Docketing

Delete	Event	Number	Due date	Reminder	Performed	Acknowledgement
<input type="checkbox"/> All None						
<input type="checkbox"/>	<input type="checkbox"/> Ciba Expiration		14 Mar 2020			
<input type="checkbox"/>	<input type="checkbox"/> Expiry date		14 Mar 2020			
<input type="checkbox"/>	<input type="checkbox"/> Petition		20 Apr 2008			
<input type="checkbox"/>	<input type="checkbox"/> Petition					
<input type="checkbox"/>	<input type="checkbox"/> Status Check		11 Jan 2008		20 Feb 2008	27 Feb 2008
<input type="checkbox"/>	<input type="checkbox"/> Petition					
<input type="checkbox"/>	<input type="checkbox"/> Reminder Letter	09/525158			11 Sep 2007	
	Response to				15 Dec 2005	

		Office Action (3 Months)	!!!	12 Jun 2001			26 Jun 2002	
		Response to Office Action (3 Months)	!!!	21 Jul 2001			26 Jun 2002	
		Submission to PTO	Ciba	16 Jul 2000			26 Jun 2002	
		Information disclosure statement	Ciba	14 Jun 2000			26 Jun 2002	
		Response to office action (2 months)	US	10 May 2002			10 May 2002	
		Office action (2 months) Mail Date	Ciba				10 Mar 2002	
		Office action	PATSYS	12 Jun 2001			21 May 2001	
		Filed	09/525158				14 Mar 2000	
		Filing decision					01 Jan 1980	

Cancel | Save



Martha-J Martin/CV/Novartis
06/09/2008 12:38 PM

To: Jian Zhou/CV/Novartis@PH
cc
bcc
Subject: Fw: Question about Patsy Docketing


FYI

Martha J. Martin
CIBA Vision Corporation
Patent Department
11460 Johns Creek Parkway
Duluth, GA 30097
Phone: +1 678-415-3334
Fax: +1 678-415-3068
Email: martha-j.martin@cibavision.com

CIBA VISION

----- Forwarded by Martha-J Martin/CV/Novartis on 06/09/2008 12:38 PM -----

Linda Rothwell/GP/Novartis
06/09/2008 09:30 AM

To: Martha-J Martin/CV/Novartis@PH
cc
Subject: Re: Question about Patsy Docketing 

That is a foreign filing docket date, which was always entered by Basel.

Linda Rothwell
Novartis Pharmaceuticals Corporation
PH, LGL-Patent Data Mgmt
USEH, 104-3J26
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080
USA
Phone: +1 862 7787906
Fax: +1 973 7818064
Email: linda.rothwell@novartis.com

 **NOVARTIS**

Martha-J Martin/CV/Novartis



Martha-J Martin/CV/Novartis
06/09/2008 07:51 AM

To: Linda Rothwell/GP/Novartis@PH
cc
Subject: Question about Patsy Docketing

Jian had a question about what "Reminder Letter" (performed December 15, 2005) indicates for

application number 09/525,158. What was this used for?

Thanks,
Martha

Martha J. Martin
CIBA Vision Corporation
Patent Department
11460 Johns Creek Parkway
Duluth, GA 30097
Phone: +1 678-415-3334
Fax: +1 678-415-3068
Email : martha-j.martin@cibavision.com

CIBA  VISION™

(C)

CASE
DIVISION OF
CONTINUATION IN PART OF

PCT
FILED

SERIAL NO.
FILED
09/525,158

INVENTOR Hitt, Thomas, et al
SERIAL NO. 09/525,158 FILED
TITLE Organic Compounds

ASSIGNEE

ASSIGNMENT RECORDED
09/280,510 filed 3/30/99
60/83,047 filed 3/14/00

REEL FRAME

OFFICE ACTIONS	AMENDMENTS
3/14/00 - Filed Case	
EL282111607US	
5/16/00 - Missing Pcto	
5/16/00 - Missing Receipt	
6/7/00 - Response to Miss Pcto	
6/21/00 - Filing Receipt	
8/30/00 - Filed IDS	
3/12/01 - Office Action	
4/8/01 - Response to Office Action ^{Amenda.}	
6/21/01 - received notice of non-comp.	
Amendment (37 CFR 1.121)	
7/3/01 - Responded to notice of non-compliance amendment	
4/5/02 - Notice of Abandonment	
5/16/02 - Response to notice of Abandonment	
Petition to Withdraw Holding of ABD.	
30 04 02 Postcard	
09-11-07 - Petition to Revive Application	
Abandoned Unintentionally	
02-20-08 - Petition Dismissed	

ALLOWED FINAL FEE PAID

PATENT NO. DATE

10# 97047

09/525,158

CONFIDENTIAL

D1



Novartis Corporation
Interoffice Correspondence

Telephone: 770-418-3173
Fax: 770-418-3068

Date: June 7, 1999

To: Mike Dammann Lance Lipscomb
Peter Herbrechtsmeier Scott Meece
Barbara Heyl Paul Nicolson
Stuart Heap Jurgen Vogt
John Lally Greg White

From: Jörg Dietz
Mike Lee

Subject: **Optics Intellectual Property Steering Committee
Second Quarter Meeting - June 9, 1999
9:00 a.m. - 12:00 noon - JCA - International Video Conference Room**

Attached is an outline of the topics for discussion at the June IPSC meeting. The meeting will be held in the International Video Conference Room (JCA-4N) and a Basle location.

Attachments

c: Glen Bradley
Kim Brazzell
Karen Copeland
Mike Glynn
Steve Schuster

CONFIDENTIAL

INTELLECTUAL PROPERTY STEERING COMMITTEE

SCHEDULE FOR MEETING

9:00 a.m. - 12:00p.m.

- I. OPEN ISSUES FROM MARCH MEETING
- II. ALL TRADEMARK ISSUES
- III. LITIGATION & OPPOSITION ISSUES
- IV. MAINTENANCE ISSUES
- V. CURRENT PREPARATION AND PROSECUTION ISSUES
- VI. OPINIONS & ADVICE
- VII. BUSINESS DEVELOPMENT & LICENSING

ATTACHMENTS

Attachment A - Entscheidlisten (Decision List) (sent 5/27/99)
Attachment B - Foreign Filing Country Lists

CONFIDENTIAL

I. ACTION ITEMS FROM DECEMBER 1998 MEETING

ACTION ITEM	DUE DATE	COMPLETED	RESPONSIBLE PARTY/PARTIES
			M. Lee
			Meece
			Lee
			Vogt
			Lee
			Dietz
			Lee
			Lee
			Liphardt
			Dietz
			Lee

II. ALL TRADEMARK ISSUES

III. LITIGATION & OPPOSITION ISSUES

A. OPPOSITION

Ot

B. PENDING LITIGATION**C. QUESTION OF INFRINGEMENT****IV. MAINTENANCE ISSUES**

A. Entscheidlisten (Decision List) - Sent to attendees.

V. CURRENT PREPARATION / PROSECUTION ISSUES**A. U.S. PREPARATION & PROSECUTION**

1. Preparation Prioritization
2. Recently Filed
 - a) CL/V-30880/P1/CGV2112 - Hirt, et al, Organic Compounds
3. Recently issued patents, notice of allowance, issue notification:

Issued Patents - U.S.:

Case	Inventor	Title
CL/V-19790	Boneberger, et al	Process and Apparatus for the Manufacture of a Contact Lens (Patent No. 5,894,002 - 4/13/99)

Notice of Allowance:

Case	Inventor	Title
CL/V-20321	Mueller, B.	Crosslinked Polymers Containing Salt Structures (08/875,530)
CL/V-20676	Nicolson, et al	Extended Wear Ophthalmic Lens (09/108,714)

B. NON-U.S. PREPARATION & PROSECUTION

1. Patent Applications filed since last IPSC
 - a) CL/V-30880/CGV2112 - Priority March 30, 1999 - Dangling Chains (Hirt et al)

CONFIDENTIAL

2. Foreign filings (decisions due)

(P)

ring

3. PCT: Entering of National Phase (decisions due)

a) (

umber

b) (

ity
ision

c) C
A

ion-
CV/3.

d) C
(l
C

uilding
was

4. EP Patents Allowed - Decision on National Validation Due

a) C
m

ction

b) C

c) C
(l

etal (l

d) C
m

PVA

e) C

f) C

CONFIDENTIAL

5. Patents issued since last IPSC (other than US patents)

This information will be reported at September IPSC.

6. Partial or Worldwide Abandonment (decisions due)

VI. OPINIONS & ADVICE

VII. BUSINESS DEVELOPMENT & LICENSING

VIII. MISCELLANEOUS

- 1999 IPSC Schedule - 9:00 - 12:00 noon (Atlanta time)

September 15, 1999

December 8, 1999

CONFIDENTIAL

M	=	Maintain in all countries.
CV/B	=	Maintain on blocking list.
CV/D	=	Maintain on defensive list.
ABD	=	Abandon case in all countries.
LIC	=	Offer to Optics Licensing and decide on abandonment if no interest at IPSC.
US	=	Maintain in U.S. only.

[illegible]

CONFIDENTIAL

Attachment B

Foreign Filing Standard Country Lists CV/1, CV/2, CV/3, CV/4, CV/D and CV/B

[illegible]

CONFIDENTIAL

CV/1	CV/2	CV/3	CV/4	CV/D	CV/B
US: USA *	US	US	US	US	US

* designates: country can be designated in a PCT patent application as of September 1997

CONFIDENTIAL

CONFIDENTIAL

CONFIDENTIAL



Novartis Corporation
Interoffice Correspondence

Telephone: 678-415-3173
Fax: 678-415-3068

Date: December 23, 1999

To: Erich Bauman
Olivia Brown
Mike Dammann*
Lily He
Barbara Heyl*
John Lally (C. Morris*)

Lance Lipscomb*
Scott Meece*
Paul Nicolson*
Tom Paul*
Jürgen Vogt
Steve Wilkin

From: Mike Lee*
Rob Gorman*
Jörg Dietz*

Subject: **Optics Intellectual Property Steering Committee
Fourth Quarter Meeting - December 8, 1999
Summary**

Attached is a summary of the December 1999 IPSC meeting.

Attachment

c: Glen Bradley
Kim Brazzell
Peter Herbrechtsmeier
Anneliese Hassenbürger*
Stuart Heap
Bernd Liphardt
Robin Terrell

Next Meeting: March 8, 2000

9:00 a.m. - 12:00 noon

International Video
Conference Room - JCA - 4N

*Denotes attendees.

30167 -> CV/B unless P. Habeshawi address diff K

CONFIDENTIAL

1) NEW ACTION ITEMS

ACTION ITEM	DUE DATE	COMPLETED	RESPONSIBLE PARTY/PARTIES
1. Send out email reminder regarding P. 11. " " "			
2.			BT
3.			
4.			
5.			ice
6.			
7.			
8.			
9.			
10.			
11. if product is still in use.			W. B. 11.11.11

CONFIDENTIAL

III. LITIGATION / OPPOSITION ISSUES

No	Title	
		on
		on
6		filed.

IV. MAINTENANCE ISSUES

V. FOREIGN FILING DECISIONS

Case No.	Project/Product	Filing List	Reasoning
CL/V-30880/CGV2112		CV/D	Oxacon / Dangling chains
			Is

VI. PCT NATIONAL PHASE ENTRY DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
CL			
CL			

VII. EP VALIDATION DECISIONS

Case No.	Project/Product	Validate in EP?	Reasoning
CL/V-		yes, all countries	on

CONFIDENTIAL

VIII. MAINTENANCE DECISIONS (Entscheidlisten)

[illegible]

NOTE:

2000 IPSC OPTICS

March 8, 2000

June 14, 2000

September 6, 2000

December 6, 2000

9:00 - 12:00 noon

JCA - 4N - International Video Conference Room

Memorandum



Date: April 17, 2001

To: Erich Bauman
Olivia Brown
Barbara Heyl*
Antoinette Lachat
John Lally*
Karen Lindley*

Lance Lipscomb*
Scott Meece*
Paul Nicolson
Tom Paul
Jürgen Vogt*

General Patent Counsel
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097
richard.gearhart@cibavision.novartis.com
phone 678-415-3650
fax 678-415-3068

From: Jörg Dietz*
Richard Gearhart*
Rob Gorman*

Subject: Optics Intellectual Property Steering Committee
First Quarter Meeting - March 7, 2001
Summary

Attached is a summary of the March 7, 2001 IPSC meeting.

Attachments

c: Glen Bradley
Stuart Heap
Peter Herbrechtsmeier
Robin Terrell

Remaining 2001 IPSC Meetings: June 6;
September 5; December 5


* Denotes attendees.

Memorandum

I. ACTION ITEMS FROM MARCH MEETING

ACTION ITEM	DUE DATE	COMPLETE	RESPONSIBLE PARTY/PARTIES
1. for C			J. Lally
2. to			R. Gearhart
3. Send Lance Lipscomb the specification of CV 150, for review.			R. Gearhart

II. FOREIGN FILING DECISIONS

Case No.	Project/Product	Filing List	Reasoning
<div style="display: flex; align-items: center;"> <div style="margin-right: 10px;"> <p>one from US</p>  </div> <div style="border: 1px solid black; height: 200px; width: 100%;"></div> </div>			

III. PCT NATIONAL PHASE ENTRY DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
CL/V-30		LNS-10	
CL/V-30	IE 6Z	LNS-Man + ID	
CL/V-30		LNS-10 + IE	
CL/V-30		LNS-B6	
CL/V-30880		LNS-B6	
CL/V-30		LNS-Manu	
SU/V-31		SUV-14	
SUV-31		SUV-35	
WJ - 76		LNS 10	
WJ - 76			See action item.

Memorandum

IV. EP VALIDATION DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
CLV-20		S	
CLV-19		S	
CLV-30		S	

Memorandum

DECISION LIST

VII. MAINTENANCE DECISIONS (Entscheidlisten)

Basel Case No.	CIBA Vision No.	IPSC Decision 3/01	Reason
CLV- 161			
CLV 162			
CLV- 168			
CLV 173			
CLV- 178			
CLV 184			
CLV- 188			
CLV 193			
CLV 194			
CLV- 197			
CLV 197			
CLV- 201			
CLV 202			
CLV 202			
CLV- 202			
CLV 202			
CLV- 202			
CLV 206			
CLV 206			
CLV- 206			
CLV 206			
CLV- 210			
CLV 210			
CLV- 211			
CLV 211			
CLV- 301			
CLV 301			
CLV- 301			
CLV 301			
CLV- 302			
CLV 303			
CLV- 303			
CLV 307			
CLV- 307			
CLV 307			
CLV- 311			
CLV 311			

Memorandum

Basel Case No.	CIBA Vision No.	IPSC Decision 3/01	Reason
CL/V- 31			
CL/V- 31			
CL/V- 31			
CL/V- 31			
CL/V- 31			
CL/V- 31			
CL/V- 31			
CL/V- 31			
LP/V- 15		M - All	G
LP/V- 16		M - All	C
LP/V- 17		M - All	M
LP/V- 17		M - CV/B	E
LP/V- 17		M - US	
LP/V- 17			
LP/V- 17		M - US	
LP/V- 20		M - All	Let the US.
LP/V- 30			
SU/V- 19		M - All	Dispute
SU/V- 21		M - CV/B	
SU/V- 30		M - All	
SU/V- 31		M - All	

D4

Memorandum



Date: July 19, 2001

To: Erich Bauman
Barbara Heyl
Antoinette Lachat
John Lally*
Karen Lindley*
Roger Lopez*
Scott Meece
Lance Lipscomb
Tom Paul
Jürgen Vogt*

General Patent Counsel
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097
richard.gearhart@cibavision.novartis.com
phone 678-415-3650
fax 678-415-3068

From: Jörg Dietz*
Richard Gearhart*
Rob Gorman*
Jian Zhou*

Subject: Optics Intellectual Property Steering Committee
Second Quarter Meeting - June 6, 2001
Summary

Attached is a summary of the June 6, 2001 IPSC meeting.

Attachments

c: Glen Bradley
Stuart Heap
Peter Herbrechtsmeier
Robin Terrell

Remaining 2001 IPSC Meetings:
September 5; December 5

* Denotes attendees.

Memorandum

I. ACTION ITEMS FROM JUNE MEETING

ACTION ITEM	DUE DATE	COMPLETE	RESPONSIBLE PARTY/PARTIES
1. a			Gearhart
b;			Dietz
2. de			P. Nicolson
3.			J. Dietz
4.			J. Dietz
5			R. Gearhart
6			R. Gearhart
7			R. Gearhart
8			R. Gearhart
9			J. Dietz
E			P. Nicolson
			R. Gearhart
			R. Gearhart
			R. Gearhart/J. Dietz
			R. Gearhart/J. Dietz
			R. Gorman

II. FOREIGN FILING DECISIONS

Case No.	Project/Product	Filing List	Reasoning
CL/V-31		LNS B6	See action item.
CL/V-31		LCP14	See action item.
LP/V-31		LCP 36	
LP/V-31		LCP14	See action item.
CL/V-31		CLR 11	See action item.
CL/V-31		LNS 10	
CL/V-31		LNS Manu	

Memorandum

LP/V-31		LCP 36	
---------	--	--------	--

III. PCT NATIONAL PHASE ENTRY DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
CLV-317 WE		CLR 18	See action item.
SU/V-30	Artificial Cornea	SUR B6	See action item.
CLV-310 VE		LNS Manu	
CLV-311		LNS B6	
CLV-312		LNS 10	
CLV-313		LNS B6	

IV. EP VALIDATION DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
CLV-300		LNS23+IE	See action item.
CLV-19		LNS B6	
CLV-21		LNS 10	
CLV-20		LNS B6	

DECISION LIST

VII. MAINTENANCE DECISIONS (Entscheidlisten)

Basel Case No.	CIBA Vision No.	IPSC Decision 6/01	Reason
CLV- 16		M - LNS B6	
CLV- 16		M - LNS B6	
CLV- 16	CGV	M - LNS B6	
CLV- 16	CGV	ABD or LNSB6	See action item.
CLV- 17	CGV	M - LNS B6	See action item.
CLV- 17	CGV	ABD	
CLV- 17	CGV	ABD	
CLV- 17	CGV	R - LNS B6	See action item.
CLV- 17	CGV	M-LNSB6	
CLV- 17	CGV	M-US	
CLV- 17	CVE	M - LNS B6	
CLV- 17	CVE	M - LNS B6	See action item.
CLV- 17	CVE	M - LNS Manu	
CLV- 18	CVE	M - US	
CLV- 18	CVE	M - LNS B6 + NL	

Memorandum

Basel Case No.	CIBA Vision No.	IPSC Decision 6/01	Reason
CL/V 18	CGV 1503	M - ALL	
CL/V- 19	CVE 48	ABD	See action item.
CL/V 19	CGV 1806	M - LNS B6	
CL/V 19		M - LNS B6	
CL/V- 19	CVE 48	M - ALL	
CL/V 20	CVE 52	M - ALL	
CL/V- 20		M - LNS B6	Backup for DAILIES.
CL/V 20		M - LNS B6	
CL/V- 20		M - ALL	
CL/V 20		M - ALL	
CL/V- 20		M - ALL	
CL/V 20		M-ALL	
CL/V- 20	CGV 1507	M - ALL	
CL/V 21	CVE 56	R - LNS 23 + IE	
CL/V- 21	CVE 56	M - LNS Manu	
CL/V 21		M - CV/D	
CL/V- 21		M - LNS B6	
CL/V 21	CGV 1508	M - ALL	
CL/V- 30	CGV 1809	R - LNS 23	
CL/V 30		M	
CL/V- 30	CVE 50	M - EP/US	
CL/V 30			Will discuss at next IPSC meeting.
CL/V- 30		M - ALL	
CL/V 30880	CGV 2442		Discuss at June 2002 meeting.
CL/V- 31			Discuss at June 2002 meeting.
CL/V 31			Discuss at June 2002 meeting.
CL/V- 31			Discuss at June 2002 meeting.
CL/V- 31			Discuss at June 2002 meeting.
CL/V- 31			Discuss at June 2002 meeting.
CL/V- 31			Discuss at June 2002 meeting.
CL/V- 31			Discuss at June 2002 meeting.
CL/V- 31	WEJ 0400		Discuss at June 2002 meeting.
CL/V- 31	WEJ 7501		Discuss at June 2002 meeting.
CL/V 31	WEJ 0202		Discuss at June 2002 meeting.
CL/V- 31	WEJ 1124		Discuss at June 2002 meeting.
CL/V 31	WEJ 1004		Discuss at June 2002 meeting.
CL/V- 31	WEJ 1004		Discuss at June 2002 meeting.
CL/V- 31	WEJ 1550		Discuss at June 2002 meeting.
CL/V- 31	WEJ 1550		Discuss at June 2002 meeting.
CL/V- 31	WEJ 1004		Discuss at June 2002 meeting.
CL/V- 31	WEJ 0400		Discuss at June 2002 meeting.
CL/V- 31	WEJ 1004		Discuss at June 2002 meeting.
CL/V- 31	WEJ 0400		Discuss at June 2002 meeting.
CL/V- 31	WEJ 0400		Discuss at June 2002 meeting.

Memorandum

Basel Case No.	CIBA Vision No.	IPSC Decision 6/01	Reason
CLV- 34	WEJ		Discuss at June 2002 meeting.
CLV- 35	WEJ		Discuss at June 2002 meeting.
CLV- 36	WEJ		Discuss at June 2002 meeting.
CLV- 37	WEJ		Discuss at June 2002 meeting.
CLV- 38	WEJ		Discuss at June 2002 meeting.
CLV- 39			Discuss at June 2002 meeting.
CLV- 40			Discuss at June 2002 meeting.
CLV- 41			Discuss at June 2002 meeting.
CLV- 42			Discuss at June 2002 meeting.
CLV- 43			Discuss at June 2002 meeting.
CLV- 44			Discuss at June 2002 meeting.
LPV- 10	CVE	M- ALL	
LPV- 11	CGV	M- LCPB6	
LPV- 12	CGV	M - ALL	
LPV- 20	CGV	M - US	
LPV- 21			Discuss at June 2002 meeting.
SUV- 22			Discuss at June 2002 meeting.
SUV- 23	MEC 4	M - ALL	
SUV- 24			Discuss at June 2002 meeting.
SUV- 25			Discuss at June 2002 meeting.
SUV- 26		R - SUR 14	See action item.
SUV- 27			Discuss at June 2002 meeting.
SUV- 28			Discuss at June 2002 meeting.

Memorandum

Foreign Filing Standard Country Lists for the LCP BUSINESS (And PROPOSED list for the SURGICAL BUSINESS,

LCP und-SUR Lists: Countries	LCP: B(6)	LCP: 14	LCP: 36		SUR B(6)	SUR 14	SUR 36
US: United States *	yes	yes	yes		yes	yes	yes
Europe:							

* designates: country can be designated in a PCT patent application as of March 2001

3/14/01

Memorandum

Foreign Filing Standard Country Lists for the LENS BUSINESS

(The WJ lists are PROPOSED only presently; "WJ" means in particular: for tinted lenses)

LNS Lists: Countries	LNS: Manu	LNS: B(6)	LNS: 10	LNS: 23	WJ 11	WJ 18	WJ 24
US: United States *	yes	yes	yes	yes	yes	yes	yes

* designates: country can be designated in a PCT patent application as of March 2001

06/01/01

D5

CONFIDENTIAL



A Novartis Company

Date: September 19, 2001

To: Erich Bauman* Lance Lipscomb
Roger Lopez* Scott Meece*
Barbara Heyl Paul Nicolson
Antoinette Lachat* Tom Paul*
John Lally Jürgen Vogt*
Karen Lindley Jörg Dietz

General Patent Counsel
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097
richard.gearhart@cibavision.novartis.com
phone 678-415-3650
fax 678-415-3068

From: Richard Gearhart
Rob Gorman
Jian Zhou

Subject: Optics Intellectual Property Steering Committee Minutes
Third Quarter Meeting – September 5, 2001
9:00 a.m. - 12:00 noon - JCA - International Video Conference Room

Summary

Attached is an outline of the topics discussed at the September 5th IPSC meeting. Please review decisions and note new action items required prior to the next IPSC meeting to be held on December 5th. The meeting will be held in the International Video Conference Room (JCA-4N) and a Basle location.

Attachments

c: Glen Bradley
Stuart Heap
Peter Herbrechtsmeier
Robin Terrell
Roland Carlen

Members Absent*

CONFIDENTIAL

INTELLECTUAL PROPERTY STEERING COMMITTEE

SCHEDULE FOR MEETING

9:00 a.m. - 12:00p.m.

- I. OPEN ISSUES FROM JUNE MEETING
- II. ALL TRADEMARK ISSUES
- III. MAINTENANCE ISSUES
- IV. CURRENT PREPARATION AND PROSECUTION ISSUES
- V. LITIGATION & OPPOSITION ISSUES
- VI. OPINIONS & ADVICE
- VII. BUSINESS DEVELOPMENT & LICENSING

ATTACHMENTS

Attachment A - Entscheidlisten (Decision List) (has been sent under separate cover)

Memorandum

I. NEW ACTION ITEMS FROM SEPTEMBER 2001 MEETING MINUTES

ACTION ITEM	DUE DATE	COMPLETED	RESPONSIBLE PARTY/PARTIES
1. Rev. 50 775000			
a)			
by			
b)			
Lit			
2. F			
F			
3.			
4.			
5. (
6. I			
7. (
8.			
9. (
10.			
11.			
12.			
13.			
14.			
15.			
16.			
17S			
			I. Paul

Memorandum

II. ACTION ITEMS COMPLETED FROM SEPTEMBER 2001 MEETING MINUTES

ACTION ITEM	DUE DATE	COMPLETED	RESPONSIBLE PARTY/PARTIES
1. CL/V-30880 - PCT Candidate. LNSB6		Completed	R. Gearhart
2.			
3.			
4.			
5.			
6. CL/V-30880 - PCT Candidate.			R. Gearhart
7. CL/V-30880 - PCT Candidate.			R. Gearhart
8. CL/V-30880 - PCT Candidate.			J. Dietz
9.			P. Nicolson
10.			R. Gearhart
11.			R. Gearhart
12.			R. Gearhart/J. Dietz
13. CL/V-30880 - PCT Candidate.		LNSB6 (+ Indonesia)	R. Gearhart/J. Dietz
14.			R. Gorman

Memorandum

III. ALL TRADEMARK ISSUES (No Update Provided)

IV. MAINTENANCE ISSUES

- A. Entscheidlisten (Decision List) – Was sent previously.
- B. WJ supplemental US list

V. CURRENT PREPARATION / PROSECUTION ISSUES

A. *U.S. PREPARATION & PROSECUTION*

- 1. Preparation Prioritization PRC Update - RIG
- 2. Recently Filed: Information Only (See **Section I** Filing Status Report).
- 3. Recently issued patents: Information Only

Patent No.	Date	Case	Inventor	Title
6,271, 233 B1	August 7, 2001	OP/V-30610/A/CGV 2024	Brazzell et al.	Method for Treating Ocular Neovascular Diseases
6, 271, 332 B1	August 7, 2001	CL/V-20677A/PCT	Lohmann et al.	Polyurethanes Made from polysiloxane/Polyol Macromers
6, 265, 509 B1	July 24, 2001	CL/V-20319/A/PCT /DIV	Muller Beat	Crosslinked Polymers
6, 259, 518 B1	July 10, 2001	CL/V-30611A/CGV 2027	Russell et al.	Wetcell Device For Inspection
6,255, 360 B1	July 3, 2001	SU/V-30898A/CVA	Domschke et al.	Process for the Manufacture of Moldings
6,221, 303 B1	April 24, 2001	CL/V-21235/A/PCT	Steinmann	Ophthalmic Moldings
6, 225, 367 B1	May 1, 2001	SU/V-30635A/ERT 15	Chaouk et al.	Polymers

Memorandum

B. NON-U.S. PREPARATION & PROSECUTION

1.

2.

d

Memorandum

i)

rising
tion

j)

k)

contact

l)

n for

3. PCT: Entering of National Phase (Decision due):

a)

v.
follow

b)

oxygen
:

4. EP Patents Allowed - Decision on National Validation Due

a)

b)

5. Partial or Worldwide abandonment (decisions due): None

VII. LITIGATION & OPPOSITION ISSUES

A. OPPOSITION

1)

proceedings before the EPO in September.

B. PENDING LITIGATION

Memorandum

1. CIBA Vision as a party

- a)

- b)

C. QUESTION OF INFRINGEMENT

VIII. OPINIONS & ADVICE

IX. BUSINESS DEVELOPMENT & LICENSING

XI. MISCELLANEOUS

Remaining 2001 IPSC Meeting December 5, 2001

Memorandum

DECISION LIST SEPTEMBER 5th Meeting

Attachment: MAINTENANCE DECISIONS (Entscheidlisten)

Basel Case No.	CIBA Vision No.	IPSC Decision 9/05	Reason
CLV			
CLV			
CLV			
CLV			
CLV			tz
CLV			tz
CLV			
CLV			
CLV			
CLV			
CLV			
CLV			
CLV			
CLV			
CLV			
CLV			
CLV			
CLV			
CLV-			
CLV			
CLV-			
CLV			
CLV-			

Memorandum

Basel Case No.	CIBA Vision No.	IPSC Decision 9/05	Reason
CL/V 3			
CL/V- 3			
CL/V 3			
CL/V- 3			
CL/V 3			
CL/V- 3			
CL/V 3			
CL/V- 3			
CL/V 3			
CL/V- 3			
CL/V 3			
CL/V- 3			
LP/V 1			
LP/V 1			
LP/V 1			
LP/V 1			
LP/V 1			
LP/V 1			
LP/V 1			
LP/V 2			
LP/V 2			
SU/V 2			

a n l
 a n l
 i e
 h R.
 h R.
 e value of
 m

w-up with
 date Oct 1st.

Memorandum

Base Case No.	CIBA Vision No.	IPSC Decision 9/05	Reason
SUN			
SUN			
SUN-			
SUN			
SUN-			
W			
Due date October 1			

Memorandum

Foreign Filing Standard Country Lists for the LCP BUSINESS

[illegible]

* designates: country can be designated in a PCT patent application as of March 2001

3/14/01

Memorandum

Foreign Filing Standard Country Lists for the LENS BUSINESS

[illegible]

* designates: country can be designated in a PCT patent application as of March 2001

06/01/01

D6

Memorandum

Minutes

Confidential



Date: July 5, 2002

To: Rafael Andino
Sheila Bodmer
Scott Hampton
Barbara Heyl*
John Lally*
Karen Lindley*
Lance Lipscomb*
Roger Lopez
Scott Meece
Michael Quinn*
Jürgen Vogt*
Daniel White

From:

Jörg Dietz*
Richard Gearhart
Rob Gorman*
Bernd Liphardt*
Robert Mueller*
Jian Zhou*

Subject:

CIBA Vision Intellectual Property Steering Committee Second Quarter Meeting – June 5, 2002 Summary

Attached is a summary of the June 5, 2002 IPSC meeting. Further meeting dates for 2002 are:

September 4, 2002
December 4, 2002

Attachments

(SEC members will obtain a summarized version)

* Denotes attendees.

→ Glen Bradley
Tim Barabe
Ivan Serogerie
Robin Terrell
Roland Carlen
Lens Business (watchdog v. Stahart Itsep?)
Sungy Boss
Lens Care Boss

Memorandum

Minutes

Confidential

I. ACTION ITEMS FROM JUNE MEETING

ACTION ITEM	DUE DATE	COMP. LETED	RESPONSIBLE PARTY/PARTIES
1			yl
2			yl
3			Andino
4			yl
5			yl/ Lipscomb
6			yl/ Lipscomb
7			l & Andino
8			l & Andino
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			
61			
62			
63			
64			
65			
66			
67			
68			
69			
70			
71			
72			
73			
74			
75			
76			
77			
78			
79			
80			
81			
82			
83			
84			
85			
86			
87			
88			
89			
90			
91			
92			
93			
94			
95			
96			
97			
98			
99			
100			

Memorandum

Minutes

Confidential

II. FOREIGN FILING DECISIONS

Case No.	Project	Filing List	Reasoning
1.			
2.			
3.			
4.			
5.			
6.			
7.			
8.			
9.			

III. PCT NATIONAL PHASE ENTRY DECISIONS

1
2
3
4
5

AU

IV. EP VALIDATION DECISIONS

Case No.	Project/Product	Entry Decision	Reasoning
-	-	-	

Confidential

V. PARTIAL OR WORLDWIDE ABANDONMENT

Steele et al.)

Block, CSIRO AU

VI. MAINTENANCE DECISIONS (Entscheidlisten)

Case No.	IPSC Decision 03/2002	Reason
CL/V-30880/CGV 2112	M - LNS B6	

Memorandum

Minutes

Confidential

	EP)		B
			B
		/	
		/	
		/	
	K)		
	s)		
	s)		
	p)		
		nī , Biorch.	B

5 Jan 54

3
B

nī, Biorum. B / AU

Memorandum

Confidential

Minutes

Foreign Filing Standard Country Lists for *

a:

٥٨

[illegible]

* designates: country can be designated in a PCT patent application as of January 2002

Memorandum

Minutes

Confidential

Foreign Filing Standard Country Lists for the LENS BUSINESS

(The CLR lists are applicable in particular for COLOURED lens cases)

LNS Lists: Countries		LNS: B6					
US: United States *	yes	yes	yes	yes	yes	yes	yes

Designated country can be designated in a PCT patent application as of January 2002

07

Memorandum

Minutes



Date: **June 30, 2003**

To: Rafael Andino*
Sheila Bodmer
Barbara Heyl*
John Lally
Karen Lindley*
Lance Lipscomb*
Roger Lopez

Scott Meece
Tom Paul
Michael Quinn*
Ming Tai
Jürgen Vogt*
Daniel White
Mary Leheny

From: Richard Ross*
Laura Fe*
Richard Gearhart*

Rob Gorman*
Bernd Liphardt
Robert Mueller*
Jian Zhou*

Subject: **CIBA Vision Intellectual Property Steering Committee
Second Quarter Meeting – June 4, 2003**

Summary

Attached is a summary of the June 4, 2003 IPSC meeting.
Quarterly meeting dates for 2003 are:

September 3, 2003
December 3, 2003

Attachments

* Denotes attendees.

Memorandum

Minutes

I. ACTION ITEMS FROM JUNE MEETING

ACTION ITEM	DUE DATE	COMPLETED	RESPONSIBLE PARTY/PARTIES
P. ST. ANTONIO			

Memorandum

Minutes

[illegible]

Memorandum

Minutes

II. FOREIGN FILING DECISIONS

[illegible]

✓	✓	nt hb
		Brocu? ✓
		Brocu? ✓
		nt HB all ✓
		✓
		Brocu? ✓
		✓
		✓
		✓
		✓
		Brocu? ✓
		✓
		✓
		nt HB ✓
		✓
		Brocu? ✓
		✓
		✓
		✓

Einfeld?

Memorandum

Minutes

III. PCT NATIONAL PHASE ENTRY DECISIONS

No.	Case	Key Term	Entry Decision
3.1			✓
3.2			CRCTT BIOCUR
3.3			BIOCUR ✓
3.4			CRCTT
3.5			✓

IV. EP VALIDATION DECISIONS

Case No.	Project/Product	Entry Decision
1.		BIOCUR
2		CRCTT / Bio
3		CRCTT / Bio
4		DT AB
5		DT AB ✓
6	long lenses	

V. Partial or Worldwide abandonment (decisions due):

Memorandum

Minutes

VI. MAINTENANCE DECISIONS (Entscheidlisten)

Case No.	IPSC Decision 06/2003	Reason
CLV-30880/CGV 2112	M - LNS B6	

Letter
on CIBASC information

✓
✓
✓
~~✓~~
✓

DIAGRAM

$$-DIAB \cap \cdot 4$$

Bio
of MBE 24
of MBE 24

	Bir
--	-----

Bio ?

	✓
	✓
	Big
	Bro

✓
Bio

	✓
	6 to
	Biocare
	6 to
	6 to
	✓

tot ✓

✓
✓

Memorandum

Minutes

[illegible]

Memorandum

Minutes

Foreign Filing Standard Country Lists

[illegible]

* designates: country can be designated in a PCT patent application as of August 2002

Minutes

(The CLR lists are applicable in particular for COLOURED lens cases)

[illegible]

* designates: country can be designated in a PCT patent application as of August 2002

18

1

Memorandum

Minutes



Date: June 21, 2004

To: Rafael Andino*
Frans Mahieu
John McNally
Kristina Meier*
Karen Lindley*
Greg White*

Lance Lipscomb*
Michael Quinn
John Lally*
Jürgen Vogt*
Peter Hagmann
MK Raheja

From: Rob Gorman*
Jian Zhou*
Karen Borrelli*

Bernd Liphardt
Robert Karl Mueller*
Laura Fe

Jennifer China*
Jocelyne Straumann* (Minutes)

Subject: **CIBA Vision Intellectual Property Steering Committee
Second Quarter Meeting – June 2, 2004**

Summary

Attached is a summary of the June 2, 2004 IPSC meeting.
Quarterly meeting dates for 2004 are:

September 1st, 2004
December 1st, 2004

Attachments

* Denotes attendees

Memorandum

Minutes

I. Trademarks Update – Kristina Meier

II. March 2004 IPSC ACTION ITEMS DISCUSSED

ACTION ITEM	RESULT
-------------	--------

March 2004 IPSC Meeting: Maintenance decisions on LP/V-Cases

(By Karen Lindley, June 4, 2004)

Case	Present Level of maintenance	Decision	Remarks
1			
1			
1			

ACTION ITEM	DUE DATE	RESPONSIBLE PARTY/PARTIES

IV. FOREIGN FILING DECISIONS

[illegible]

Case	Key Term	Entry Decision

Case	Key Term	Entry Decision
CLV-30704/CGV 2000	Alternative Oxidation synthesis	Action Item 3
CLV-30880/CGV 2112	Amphiphilic block copolymers comprising dangling chains	LNS B6 (FR, DE, GB, IT)

CLV-317:
Decision : ABD

VIII. MAINTENANCE DECISIONS (Entscheidlisten)

Case No.	IPSC Decision 06/2004	Reason
CL/V-30880/CGV 2112	M – LNS B6	Action Item 8 (Jian Zhou)

* designates: country can be designated in a PCT patent application as of August 2002

(The CLR lists are applicable in particular for COLOURED lens cases)

* designates: country can be designated in a PCT patent application as of August 2002

D9

Memorandum

Minutes



Date : September 15, 2004

To: Rafael Andino*
Walter Bassett*
John McNally
Kristina Meier
Karen Lindley
Greg White
Michael Quinn*

Lance Lipscomb*
Frans Mahieu
John Lally*
Jürgen Vogt*
Peter Hagmann
MK Raheja*

Pernis Bishoy

From: Rob Gorman*
Jian Zhou*
Karen Borrelli*

Bernd Liphardt
Robert Mueller*
Laura Fe*

Sara Carter*
Jennifer China
Jocelyne Straumann* (Minutes)

Subject : **CIBA Vision Intellectual Property Steering Committee
Third Quarter Meeting – September 1, 2004**

Summary

Attached is a summary of the September 1, 2004 IPSC meeting.
Next meeting date is :

December 1, 2004

Attachments

* Denotes attendees

Memorandum

Minutes

I. Trademarks

II. June 2004 IPSC ACTION ITEMS DISCUSSED

ACTION ITEM	RESULT
8. CL/V-30880/CGV 2112, examine against :	

Memorandum

Minutes

[illegible]

III. Open issues from September 2004 Meeting

ACTION ITEM	DUE DATE	RESPONSIBLE PARTY/PARTIES
		<p>an</p> <p>a</p> <p>el</p> <p>8</p> <p>7</p> <p>1</p> <p>g</p>
<p>4. CL/V-30880/CGV 2112, examine against . Don't think it is relevant.</p>		<p>Rob Gorman, & Jian Zhou</p>

Memorandum

Minutes

[illegible]

IV. Litigation Issues

Updates on litigation / opposition as appropriate

V. Maintenance issues

VI. Foreign Filings Decisions

Case	Key Term	Filing List
		-ID + SG)

VII. PCT: Entering of national Phase (decisions due):

Case	Key Term	Entry Decision
		lanu

Memorandum

Minutes

VII. EP Patents allowed (décisions due):

Case	Key Term	Entry Decision
		ST NC Manu
		tion
02090/CVX	peroxidase enzyme/oxidic salt/120% based on	NY DC

VII. Partial or Worldwide abandonment (decisions due):

- a. SU/V-317, Multifocal IOL, (worldwide abandonment tentatively decided) **Decision : Abd.**
- b. Diagnostic Lens Portfolio, 19 patent families

List of Diagnostic Patent Applications (August 2004)

[illegible]

Memorandum

Minutes

[illegible]

VIII. MAINTENANCE DECISIONS (Entscheidlisten)

C	004	Reason
L		Action item 17
L		
L	JS)	
L		
L		
L		
L		
(

Memorandum

Minutes

[illegible]

Memorandum

Minutes

Case No.	IPSC Decision 09/2004	Reason
C		
C		
C		
C		
C		Action Item 11
S		
S		
S		

Memorandum

Minutes

Foreign Filing Standard Country Lists for the LCP BUSINESS (as of June 10, 2004)

LCP Lists: Countries	CV-B6	CV-7		
US: United States *	yes	yes	yes	yes
Europe:				

[illegible]

* designates: country can be designated in a PCT patent application as of August 2004

Memorandum

Minutes

Foreign Filing Standard Country Lists for the LENS BUSINESS (as of June 10, 2004)
(The CLR lists are applicable in particular for COLOURED lens cases)

[illegible]

*designates: country can be designated in a PCT patent application as of August 2004

D/0

Memorandum

Minutes



Date : December 16, 2004

To: Rafael Andino* Lance Lipscomb*
Walt Bassett Frans Mahieu
John McNally* John Lally*
Kristina Meier Jürgen Vogt*
Karen Lindley* Remis Bistras*
Angelika Domschke* Peter Hagmann
MK Raheja*
Michael Quinn* Curt McKenney*

From: Rob Gorman* Bernd Liphardt*
Jian Zhou* Robert Karl Mueller*
Karen Borrelli* Laura Fe*

Sara Carter*
Jennifer China
Jocelyne Straumann* (Minutes)

Subject : CIBA Vision Intellectual Property Steering Committee
Fourth Quarter Meeting – ~~September 1st~~, 2004

December

Summary

Attached is a summary of the December 1, 2004 IPSC meeting.

Quarterly meeting dates for 2005:

March 2nd, 2005
June 1st, 2005
August 31st, 2005
November 30th, 2005

Attachments

* Denotes attendees

Memorandum

Minutes

I. Trademarks

II. September 2004 IPSC action items discussed

ACTION ITEM	RESULT
4. CL/V-30880/CGV 2112, examine against [REDACTED] Don't think it is relevant.	Done

Memorandum

Minutes

III. Open issues from December 2004 Meeting

ACTION ITEM	DUE DATE	RESPONSIBLE PARTY/PARTIES

IV. Patent Policy

The revised CIBA Vision Patent Policy was discussed and approved

V. Foreign Filing Decisions

[illegible]

Memorandum

Minutes

Case	Key Term	Filing List
		R

VI. PCT: Entering of National Phase (decisions due):

[illegible]

Memorandum

Minutes

VII. EP Patents allowed (decisions due)

Case	Key Term	Entry Decision

VIII. Further handling of DiLens Patent Applications (Proposal P. Herbrechtsmeier)

A. Licensing out candidates – Maintain until July 2005

Internal Case CL/V	Priority Date	Title/Subject Matter	Status
315			Pending in more than 30 worldwide the US (US-P
319			, EP, JP WO 02/087 429
326			T Phase: Mar 2005
326			T, National Phase:
327			T, National Phase:
328			T, National Phase Jun
328			T, National Phase Jul
328			T, Phase: Aug 2005
328			T, Phase: Aug 2005
329C			T, National Phase:
		Birth control method	

Memorandum

Minutes

Internal Case CL/V	Priority Date	Title/Subject Matter	Status
328			Reading DCT National Phase:
33			ational Phase:
33			Jan 2006
33			Feb 2006
33			Feb 2005
33			May 2005
33			June 2005
		from blood and from ocular fluid	

B. Patent families of minor interest – candidates for abandonment

31	
32	
328	5
	15
33	
	16

C. Patent families co-owned with Ehrfeld – offer to Ehrfeld/Bayer

328	Reading DCT
328	

Memorandum

Minutes

33'	35
33'	15

Decision on the further handling of the DiLens Patent Portfolio:

- Include group B patents into the licensing out candidates – maintain group A and group B patents until end of July 2005
- It was approved to offer group C patents to Ehrfeld/BAYER

IX. Maintenance Decisions (Entscheidlisten)

Case No.	IPSC Decision 4/2004	Reason
CLV-171	9 M – JP only	Subject to Gilead-Epstein agreement
CLV-182	7 M – (CV-B6)	
CLV-195	M – (CV-B6, + AU, CA)	
CLV-196	R – (CV 7) - CA	
CLV-197	M – (15 countries)	
CLV-198	M – All (37 countries)	
CLV-199	13 M – (LNS Manu)	
CLV-200	M – All (21 countries)	
CLV-201	19 M – all (= (CV-7) + IE + ES	
CLV-202	M – (CV-B6)	
CLV-203	M – (CV-B6)	
CLV-204	374 M – (CV-B6, + IE)	
CLV-205) R – (CV-B6)	
CLV-206	953 M – (CV-B6, + IE)	
CLV-207	957 M – (CV-B6, + IE)	
CLV-208	M – (CV-B6)	
CLV-209	10 M – (CV B6)	
CLV-210	2027 M – (CV-B6)	
CLV-211	2039 M – (LNS Manu)	
CLV-212	2040 M – (LNS Manu)	
CLV-213	31 M – (LNS Manu)	
CLV-214	M – (CV-B6)	
CLV-215	M – US only	
CLV-216	M – (CV-B6)	
CLV-217	R – (CV-7)	
CLV-218	M – (CV-B6)	

Memorandum

Minutes

CL/V-	R - (CV-7)	
CL/V-	M - (CV-7)	
CL/V-	M - (CV-7)	
CL/V-	M - (CV-B6)	
CL/V-	M - (CV-7)	
CL/V-	M - (CV-7)	
CL/V-	M - (CV-7)	
CL/V-	M - (CV-7)	
CL/V-	M - (CV-B6)	
CL/V-	M - (CV-7)	
CL/V-	R - (CV-B6)	
CL/V-317	ABD	
CL/V-34	M - all	Action Item
CL/V-	M - ALL (= (CV-7) + AU - IT - USA	Action Item
CL/V-	Reduce lens design to (CV-7) Keep process everywhere	
CL/V-	M - all (= AR, EP, JP, SG, US)	
LP/V-	M - All (17 countries)	
LP/V-	M - (LCP-B6)	
LP/V-	M - (LCP-B6)	
LP/V-	M - (LCP-B6)	
LP/V-	M - (CV 7) + TW	
LP/V-	M - (LCP 36)	
LP/V-	M - (CV-7) + TW	
LP/V-	M - LCP B6	
SU/V	M - SUR 14	Action Item

Memorandum

Minutes

ANNEX 1 - CV Foreign Filing Standard Country Lists

[illegible]

*designates: country can be designated in a PCT patent application as of October 2004

D11

Confidential
Memorandum Minutes May 26, 2005



Date: June 15, 2005

Subject: CIBA Vision Intellectual Property Steering Committee
Second Quarter Meeting – May 26th, 2005

Distribution

Andino Rafael*	Meier Kristina
Basset Walt	Minno George
Bistras Remis*	Mueller Robert Karl*
Borrelli Karen*	Lally John*
Carter Sara	Lindley Karen*
China Jennifer	Liphardt Bernd
Domschke Angelika*	Lipscomb Lance
Fe Laura*	Raheja MK*
Gorman Rob*	Quinn Michael
Hagmann Peter	Vogt Juergen
Mahieu Frans	Ujak Vanessa (Minutes)*
McKenney Curt*	Jian Zhou*

Legend

- | | |
|-------------------------------------------------------------------------------------|--------|
| I. Open Issues from March 2005 Meeting | p.2 |
| II. New Action Items | p.2 |
| III. Foreign Filing Decisions | p.2, 3 |
| IV. PCT: Entering of National Phase | p.3 |
| V. EP Patents allowed (decisions due) | p.3 |
| VI. Further handling of DiLens Patent Applications
(Proposal P. Herbrechtsmeier) | p.4, 5 |
| VII. Maintenance Decisions | p.6, 8 |
| Annex 1 – CV Foreign Filing Standard Country Lists | p.8 |

Summary

Attached is a summary of the May 26, 2005 IPSC meeting.

Remaining quarterly meeting dates for 2005:

August 31, 2005

November 30, 2005

* Denotes attendees

Confidential
Memorandum Minutes May 26, 2005

I. Open Issues from March 2005 Meeting

Action Items	Responsible	Result
--------------	-------------	--------

II. New Action Items

Action Items	Due Date	Responsible Party/Parties
--------------	----------	---------------------------

III. Foreign Filing Decisions

Case	Key Term	Filing List
CLV-0000000000	US Patent for making customized colored glass contact	US 22 + MY + IN
CLV-		
CLV-		
CLV-		
CLV-		
CLV-		
CLV-0000000000	US Patent for improved contact lenses	

Confidential
Memorandum Minutes May 26, 2005

Case	Key Term	Filing List
CLV-3		CLV-7
CLV-3		
CLV-3		
CLV-3		
CLV-3		
CLV-3	Contact lens design for large amplitude translation	CLV-7

IV. PCT: Entering of National Phase:

Case	Key Term	Entry Decision
CLV		
CLV		
CLV		
CLV		
CLV	et al.)	

V. EP Patents allowed

Case	Key Term	Entry Decision
CLV-312		B, IT)
CLV-313		ES +
		B, IE, IT
LPV-320		
CLV-320		B, IT)
		IE

Confidential
Memorandum Minutes May 26, 2005

VI. Further Handling of DiLens Patent Applications (Proposal P. Herbrechtsmeier)
6.1. Group A: Licensing out candidates – Maintain until July 2005

Internal Case CLN	Priority Date	Title/Subject Matter	Status
31552/TEX	2004	Device for measuring intraocular pressure	to CV-7 nts to Dr. 0 -P
326			SA
327			ISA
328			2005
328			0 2005
329			16 National
329			17 National
332			34
333			2006 37
336			2006 e 2006
338		Measurement of blood sugar level from blood stream ocular fluid	PCT Filing: June 2005

Confidential
Memorandum Minutes May 26, 2005

6.2 Group B. Patent families of minor interest – candidates for abandonment (**Maintain until July 2005**)

Internal Case CLV	Priority Date	Title/Subject Matter	Status
319			
326			
328			
33			

Confidential
Memorandum Minutes May 26, 2005

VII. Maintenance Decisions (Entscheidlisten)

Case No.	Decision	Reason, Action Item
LPV-	M - (CV-7) - CA	
LPV-	M - (CV-7) + AU + TW	
LPV-	M - (CV-7) - CA	
LPV-	M - LCP 36	
CLV-	M - (CV-7) - CA - US	
CLV-	M - (CV-7) - CA - US	
CLV-	M - US only (tentative decision)	Action item
CLV	M - (CV-7) - CA	
CLV	M - (FR, DE, GB, IT)	
CLV	M - (CV Manu) + JP - ID - SG - MY	
CLV	M - (CV-7) - CA	
CLV	M - (CV-7)	
CLV-190	M - US only	
CLV-194	M - (CV-7) - CA	
CLV-197	ABD	
CLV-197	ABD	
CLV-198	ABD	
CLV-198	M - (CV Manu) + JP - ID - SG - MY	
CLV-203	M - (DE, US)	
CLV-203	M - (CV-7) - CA	
CL	M - (CV-7) - CA	
CL	M - (CV-7) - CA	
CL	M - (CV-7) - CA	
CL	M - (CV-7) - CA	
CL	M - (CV-7) - CA	
CL	M - (CV-7) - CA	
CL	M - US	
CL	M - US	
CL	M - DE	
CL	M - (CV-7) - CA	
CL	M - (CV-7) - CA	
CL	M - (CV Manu) + JP - ID - SG - MY	
CL	M - (CV-7) + NO + ES + SE	
CL	M - (CV-7) - CA	
CL	M - (CV Manu) + JP - ID - SG - MY	
CL	M - (CV Manu) - ID - SG - MY	
CL	M - (CV Manu) + JP - ID - SG - MY	
CLV-30880/CGV 2112	M - (CV-7) - CA	
CLV-3	M - (CV Manu) + JP - ID - SG - MY	
CLV-3	R - (CV-7)	
CLV-	M - (CV Manu) + JP - ID - SG - MY	ABD AR + TW (IPSC June 2003)
CLV-	M - (CV-7) - CA	

Confidential
Memorandum Minutes May 26, 2005

Case No.	Decision	Reason, Action Item
CL/V-31	M - (CV Manu) + JP - ID - SG - MY	
CL/V-31	M - (CV-7) + NO + ES + SE	
CL/V-31	M - (CV-7) + NO + ES + SE	
CL/V-31	M - (GB, JP, MX, US)	
CL/V-31	M - All	
CL/V-31	M - (CV-7) - CA	
CL/V-31	M - All	
CL/V-31	M - (DE + US)	IPSC June 2003: R - (DE + US)
CL/V-31	M - (CV-7) - CA	
CL/V-31	M - (CV-7)	
CL/V-31	ABD (tentative decision)	Action Item
CL/V-31	ABD (tentative decision)	Action item
CL/V-31	M - (DE + US)	
CL/V-31	M - US	
CL/V-31	M - US	
CL/V-31	M - US	
CL/V-31	M - US	
CL/V-31	M - (CV-7) - CA	
CL/V-31	M - (CV-7) - CA	
CL/V-31	M - LNS 23	
CL/V-31	M - (CV Manu) + JP - ID - SG - MY	
CL/V-31	M - (CV Manu) + JP - ID - SG - MY	
CL/V-31	M - (CV-7) + NO + ES + SE	
CL/V-31	M - (CV-7)	
CL/V-31	M - (CV Manu) + JP - ID - SG - MY	
CL/V-32	M - (AR, EP, US, TW)	
CL/V-32	M - (CV-7)	
CL/V-32	M - (CV-7)	
CL/V-32	M - (CV Manu) + JP - ID - SG - MY	
CL/V-32	M - (CV Manu) + JP + SG - ID - SG - MY	
CV/V-32L	M - (CV-7)	

Confidential
Memorandum Minutes May 26, 2005

ANNEX 1 - CIBA Vision Foreign Filing Standard Country Lists

Country:	LNS List:	CV-Manu	CV-7	LNS-23	LCP-36
US: United States*		yes	yes	yes	yes

designates: country can be designated in a PCT patent application as of April 2005

Minutes of the Second Quarter 2006 IPSC Meeting

Confidential



Date : June 23, 2006

Subject : CIBA Vision Intellectual Property Steering Committee
Second Quarter Meeting – June 2nd, 2006

Distribution

Bassett Walt*
Bielefeldt Florian*
Bistras Remis*
Borrelli Karen*
Carter Sara*
Domschke Angelika*
Gorman Rob*
Hagmann Peter
Heggen Kristin*
Lally John*
Liphardt Bernd*

Lipscomb Lance*
Mahieu Frans
McKenney Curt
Meier Kristina
Minno George*
Mueller Robert Karl*
Quinn Michael*
Raheja MK
Vogt Juergen*
Zhou Jian*

*) Signifies present at meeting

Legend

I. Open issues from the March 2006 Meeting	p. 2
II. New Action Items	p. 3
III. Foreign Filing Decisions	p. 3
IV. PCT: Entering of National Phase	p. 4
V. EP Patents allowed	p. 4
VI. Maintenance Decisions	p. 4-6
VII. DiLens Patent Applications not transferred to EyeSense AG	p. 7
Annex 1 – CV Foreign Filing Standard Country Lists	p. 8

Summary

Attached is a summary of the June 2nd 2006 IPSC Meeting.

Remaining IPSC meeting dates 2006:

- Friday, September 1, 2006
- Friday, December 1, 2006

Minutes of the Second Quarter 2006 IPSC Meeting

Confidential

I. Open Issues/Results from March 2006 Meeting

ACTION ITEM	Responsible	Result
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		

Minutes of the Second Quarter 2006 IPSC Meeting

Confidential

II: New Action items

ACTION ITEM	Responsible	Result
1. I A S		
2. I		
3. t		02/2006
4. I		02/2006
5. I		02/2006
6. I		
7. I		
8. I		02/2006

III. Foreign filing Decisions

Case First Filing	Key Term / Inventor(s)	Filing Decision (Actual Filings)
CLV-34 13.10.20		lanu PCT)
LPV-34 16.11.20		36 PCT, AR, TH,
LPV-34 16.11.20		36 PCT, AR, TH,
LPV-34 16.11.20		36 PCT, AR, TH,
CLV-34 24.11.20		lanu PCT)
CLV-34 14.12.20		PCT)

Minutes of the Second Quarter 2006 IPSC Meeting

Confidential

IV. PCT National/Regional Phase Entry Decision

Case	Key Term / Inventor(s)	Entering Decision
CLV-338		on postponed Quarter ig ction Item 1
CLV-339		on postponed Quarter ig ction Item 1

V. EP Patents Allowed: Decision on Validation in EPC Contracting States

Case	Key Term / Inventors	Validation Decision
CLV-324		
CLV-319		
CLV-313		
CLV-322		
CLV-311		
		FR, DE, GB, IT

VI. Maintenance Decisions

Provisional Decisions:

In cases for which a "provisional decision" has been taken during an IPSC Meeting, two weeks are provided for reviewing such a "provisional decision". If the responsible IPSC member wants to amend a provisional decision, please inform Rob Gorman (cc: Robert Karl Mueller) accordingly.

In the absence of instructions for amending a "provisional decision", the provisional decision becomes permanent and any measures for implementation of the decision may be executed.

Case No.	Decision	Reason, Action Item
LPV-168		
LPV-174		
LPV-315		
LPV-31		

Minutes of the Second Quarter 2006 IPSC Meeting

Confidential

CLV-169		
CLV-169		
CLV-174		
CLV-174		
CLV-179	ABD (provisional decision)	New Action Item No. 2
CLV-17	R to (DE, GB, IE, US) (ABD FR, JP)	
CLV-18	R to (US only) (provisional decision)	New Action Item No. 3
CLV-18	M - (CV-7)	
CLV-19	M - (CV-7, -CA)	
CLV-19	M - (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-20	M - (DE, US)	
CLV-20	M - (CV-7, -CA)	
CLV-20	M - (CV-7, -CA)	
CLV-20	M - (CV-7, -CA)	
CLV-20	M - (CV-7, -CA)	
CLV-20	M - (CV-7, -CA)	
CLV-20	M - (CV-7, -CA)	
CLV-21	M - (DE only)	
CLV-21	M - (CV-7, -CA)	
CLV-21	M - (CV-7, -CA)	
CLV-21	M - (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-30	M - (CV-7, +NO, +ES, +SE)	
CLV-30	M - (CV-7, -CA)	
CLV-30	M - (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-30	M - (DE only)	
CLV-30	M - (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-30880/CGV 2112	M - (CV-7, -CA)	
CLV-308	M - (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-312	M - (CV-7)	
CLV-313	M - (CV-7, +AR, +IE, +ES, +SE, +TW)	
CLV-313	M - (CV-7, -CA)	
CLV-313	M - (CV-Manu, +JP, -CN, -ID, -SG, -MY)	
CLV-313	M - (CV-7, +NO, +ES, +SE)	
CLV-316	M - (CV-7, +NO, +ES, +SE)	
CLV-317	M - (GB, JP, MX, US)	
CLV-317	M - all	
CLV-317	M - (CV-7, -CA)	
CLV-317	M - (AR, BR, CA, MY)	
CLV-317	R - (US only) (ABD EP) (provisional decision)	New Action Item No. 7

Minutes of the Second Quarter 2006 IPSC Meeting
Confidential

CLV-31	R – (US only) (ABD EP, JP) (provisional decision)	New Action Item No. 7
CLV-31	R – (US only) (ABD EP, JP) (provisional decision)	New Action Item No. 7
CLV-31	ABD (provisional decision)	New Action Item No. 8
CLV-31	ABD (provisional decision)	New Action Item No. 8
CLV-31	M – (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-31	M – (CV-7, -CA)	
CLV-31	M – (LNS-23)	
CLV-31	M – (CV-Manu, +JP, -CN, -ID, -SG, -MY)	
CLV-31	M – (CV-Manu, +JP, -CN, -ID, -SG, -MY)	
CLV-31	M – (CV-7, +NO)	
CLV-31	M – (CV-7)	
CLV-31	M – (CV-7, -CA)	
CLV-32	M – (LNS-23)	
CLV-32	M – (CV-7)	
CLV-32	M – (CV-7)	
CLV-32	M – (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-32	M – (CV Manu, +FR, +JP, -CN, -ID, -SG, -MY)	
CLV-32	M – (CV-7)	
CLV-32	M – (CV-7)	
CLV-32	M – (EP, US)	
CLV-32	M – (EP, US)	
SUN-31	M – (CV-7, -CA)	Galín

Minutes of the Second Quarter 2006 IPSC Meeting
Confidential

VII. DiLens Patent Applications not transferred to EyeSense AG

Internal Case CLN	Priority Date	Title/Subject Matter	Status
321			Pat. No. 6,000,410/024035
322			
323			
324			
325			

Minutes of the Second Quarter 2006 IPSC Meeting
Confidential

ANNEX 1 - CIBA Vision Foreign Filing Standard Country Lists (last revised Nov. 30, 2005)

[illegible]

⁷ Country can be designated in a PCT patent application as of November 2005

**) PCT will enter into force for Malaysia on August 16, 2006

Minutes of the Q2 2007 IPSC Meeting
Confidential



Date : June 21, 2007

Subject : CIBA Vision Intellectual Property Steering Committee
Q1 2007 Meeting – June 7, 2007

Distribution

Aziz Tariq
Bassett Walt*)
Bielefeldt Florian
Brayley Ann
Forman Jeff
Gorman Rob*)
Hagmann Peter
Hu Sheng
Lipscomb Lance
Mallari Pamela*)

Martin Martha*)
McKenney Curt*)
Meece Scott
Minno George
Raheja MK*)
Vogt Juergen*)
Winterton Lynn*) (R.Scott attended for Lynn)
Zhou Jian*)

*) Signifies present at meeting

Legend

1A.	Open issues from the Q1 2007 IPSC Meeting	p. 2
1B.	New Action Items	p. 2-3
2.	Maintenance Issues	
2.1	Foreign Filing Decisions	p. 3
2.2	PCT: Entering of National/Regional Phase	p. 4
2.3	EP Patents allowed	p. 4
2.4	Maintenance Decisions	p. 5-6
	Annex 1 – CV Foreign Filing Standard Country Lists	p. 7

Summary

Attached is a summary of the June 7, 2007 IPSC Meeting.

Further IPSC meeting dates 2007:

- Thursday, September 6, 2007
- Thursday, December 6, 2007

Minutes of the Q2 2007 IPSC Meeting
Confidential

1A. Open Issues/Results from last IPSC Meeting

ACTION ITEM		Responsible	Status / Due date
1			
2			
3			
4			
5			
6			
7			
8			
9			

1B. New Action Items

ACTION ITEM		Responsible	Status / Due date
1			
2			
3			
4			
5			
6			

Minutes of the Q2 2007 IPSC Meeting

Confidential

8	
9	
1	AU,
1	
1	
1	

2. Maintenance Issues

2.1 Foreign Filings

Case First Filing	Keyword	Internal Title // Inventor(s)	Decision
			+
			+
			S
			S
			S
			S

Confidential

2.2 PCT: Entering of National/Regional Phase

Case First Filing	Keyword	Internal Title / Inventor(s)	Decision
341			OK/Memo
341			
341			
34:			
34:			
34			
34		(V. Heymann, G. Lassig, R. Biehl)	

2.3 EP Patents Allowed (Decisions on the Validation of the Patent in EPC Contracting States)

Case First Filing	Keyword	Internal Title / Inventor(s)	Decision
Lens Care			
321			

Case First Filing	Keyword	Internal Title / Inventor(s)	Decision
Contact Lens			
31f			
32			
32			

Minutes of the Q2 2007 IPSC Meeting

Confidential

2.4 Maintenance Decisions

Provisional Decisions: 2 weeks are provided for reviewing "provisional decisions". If the responsible IPSC member wants to amend a provisional decision, please inform Rob Gorman (cc: Florian Bielefeldt) accordingly. In the absence of instructions for amending a "provisional decision", the provisional decision becomes final and any measures for implementation of the decision may be executed.

Case	Keyword	Decision	Reason
Lens Care			
168			
174			U, TW (prov.) tem 10
313			
317			

Case	Keyword	Decision	Reason
Con			
169		M – (CV-7, -CA, -US)	
184		M – (CV-7)	
191		M – (CV-7, -CA)	Action Item 11
30880/CGV 2112	Silicone Containing	M – (CV-7, -CA)	
313		M – (CV-7, +NO, +ES, +SE)	
303		M – (CV-7, +NO, +ES, +SE)	
313		M – (US only)	
313		M – (CV-7, +AR, +IE, +ES, +SE, +TW)	
313		M – (CV-7, -CA)	
318		M – (CV-7, -CA)	
322		M – (LNS-23)	
322		M – (CV-7)	
203		M – (CV-7, -CA)	
203		M – (CV-7, -CA)	
203		M – (CV-7, -CA)	
203		M – (CV-7, -CA)	
203		M – (CV-7, -CA)	
203		M – (CV-7, -CA)	
212		M – (CV-7, -CA)	
212		M – (CV-7, -CA)	
312		M – (CV-7)	
317		M – (US only)	
318		M – (LNS-23)	
174		M – (CV-7, -CA)	
203		R – (US Only)	ABD DE
316		M – (CV-7, +NO, +ES, +SE)	
317		M – (GB, JP, MX, US)	Action Item 12

Minutes of the Q2 2007 IPSC Meeting
Confidential

Case	Keyword	Decision	Reason
		M – (US only)	
		M – (US only)	
		M – (CV-7)	
		M – (DE, GB, IE, US)	
		M – (US only)	
		M – (US, JP, DE, GB, FR, IE)	
		M – (DE only)	
		M – (US, JP, DE, GB, FR, IE)	
		M – (CV-7, -CA)	
		R – (US, JP, DE, GB, IE)	ABD FR
		R – (US, JP, DE, GB, IE)	ABD FR
		R – (US, JP, DE, GB, IE)	ABD FR
		ABD (Prov)	Action Item 13
		M – (US, JP, DE, GB, IE)	
		M – (CV-7, +NO)	
		M – (EP, JP, US)	
		M – (CV Manu, -MY)	
		M – (US only)	
		M – (CV-7, -CA)	
		M – (US only)	
		M – (US only)	
		M – (CV-7)	
		M – (CV-7)	
		M – (CV-7)	
		M – (CV-7, +AU)	
		M – (US only)	
		M – (US only)	
		M – (US only)	
		M – (US only)	
		M – (US only)	
		M – (US, JP, DE, GB, IE)	
		M – (US only)	
		M – (EP, US)	
		M – (EP, US)	
		R – (US, JP, DE, GB, IE)	ABD FR
		R – (IE, US)	ABD FR, DE, GB, JP
		M – (US, JP, DE, GB, FR, IE)	
		M – (CV-7, -CA)	Action Item 5

Minutes of the Q2 2007 IPSC Meeting
Confidential

ANNEX 1 - CIBA Vision Standard Country Lists (last revised Nov. 30, 2005)

Country Variant	CV-Manu	CV-7	LNS-23	LCP-36
US: United States*	yes	yes	yes	yes

designates: country can be designated in a PCT patent application (status as of August 16, 2006)

Decision List

for abandonment

Section

CIBA Vision (Prio JAN-MAR)

CL/V -30880/CGV 2112

Page 1 of 2

Priority 30.03.1999 USA

Patent Specialist LIP

Section Subgroup LNS

Inventor(s) T. Hirt
T. Holland

J. Schremmer

D. Lohmann

Contracts 99/02/ Contract active maint. relevant

Short description of the invention

BULK MATERIAL WITH WETTABLE SURFACE
WITHOUT COATING; DANGLING CHAINS☐ Case abandonment world-wide

Decision to abandon

Country	Ident. code	Fil.proc.	Status	Fee due	Expiry	Owner	Fee Ind.	Costs CHF
<input type="checkbox"/> Europe	A	EuPCT	pending	03/2003	2020	NOV	4	593
Austria	A	EuPCT	pending		2020	NOV		
Belgium	A	EuPCT	pending		2020	NOV		
Cyprus	A	EuPCT	pending		2020	NOV		
Denmark	A	EuPCT	pending		2020	NOV		
Finland	A	EuPCT	pending		2020	NOV		
France	A	EuPCT	pending		2020	NOV		
Germany	A	EuPCT	pending		2020	NOV		
Great Britain	A	EuPCT	pending		2020	NOV		
Greece	A	EuPCT	pending		2020	NOV		
Ireland	A	EuPCT	pending		2020	NOV		
Italy	A	EuPCT	pending		2020	NOV		
Luxemburg	A	EuPCT	pending		2020	NOV		
Monaco	A	EuPCT	pending		2020	NOV		
Netherlands	A	EuPCT	pending		2020	NOV		
Portugal	A	EuPCT	pending		2020	NOV		
Spain	A	EuPCT	pending		2020	NOV		
Sweden	A	EuPCT	pending		2020	NOV		
Switzerland	A	EuPCT	pending		2020	NOV		
<input type="checkbox"/> Japan	A	PCT	pending		2020	NOV		
<input type="checkbox"/> USA	A	PCT	pending		2020	NOV		

Total costs 593

Costs until expiry 21,745

'Costs until expiry' is a rough estimate based on the data of the case which were available on the day of the print-out. It consists only of renewal fees and does not contain any other fee, such as prosecution, translation, printing fees etc. It is further important to know that in many countries renewal fees first become due after grant. These potential renewal fees are not contained in the 'Costs until expiry'. In the European patent procedure renewal fees have to be paid centrally for the pending European patent application only. As soon as the grant has taken place, renewal fees will be due for each European designation individually. Such potential renewal fees are not contained in the 'Costs until expiry' if the European patent application is pending on the date of the print-out.

No Decision

Country	Ident. code	Fil.proc.	Remarks
PCT	A	PCT	abandoned 2001
USA	P1		abandoned 2000

Section
CIBA Vision (Prio JAN-MAR)

Decision List

for abandonment

CLV -30880/CGV 2112

Page 2 of 2

No Decision

Country	Ident. code	Fil.proc.	Remarks
USA	P1/PROV		expired 2000

Examination

Country	Ident. code	Fil.proc.	Due date
Japan	A	PCT	28.03.2007

Decision date:

Signature:
(according to section regulations)

Patsys

Decision List
for abandonment

05.05.2004
Page 60/138

Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CLV -30880/CGV 2112

Priority 30.03.1999 USA
Patent Specialist LIP
Section Subgroup LNS

Inventor(s) T. Hirt J. Schremmer
T. Holland D. Lohmann
Contracts 99/02/ Contract active maint. relevant

Short description of the invention
**BULK MATERIAL WITH WETTABLE SURFACE
WITHOUT COATING; DANGLING CHAINS**

Products, compounds, projects
~~CLV (11.10.03)~~

Invention category Product

Utility code 4 BIO

☐ Case abandonment world-wide

Decision to abandon

Country	Ident. code	Fil.proc.	Status	Fee due	Expiry	Owner	Fee ind.	Costs CHF
<input type="checkbox"/> Europe	A	EuPCT	pending	03/2005	2020	NOV	6	1105
Austria	A	EuPCT	pending		2020	NOA		
Belgium	A	EuPCT	pending		2020	NOV		
Cyprus	A	EuPCT	pending		2020	NOV		
Denmark	A	EuPCT	pending		2020	NOV		
Finland	A	EuPCT	pending		2020	NOV		
France	A	EuPCT	pending		2020	NOV		
Germany	A	EuPCT	pending		2020	NOV		
Great Britain	A	EuPCT	pending		2020	NOV		
Greece	A	EuPCT	pending		2020	NOV		
Ireland	A	EuPCT	pending		2020	NOV		
Italy	A	EuPCT	pending		2020	NOV		
Luxemburg	A	EuPCT	pending		2020	NOV		
Monaco	A	EuPCT	pending		2020	NOV		
Netherlands	A	EuPCT	pending		2020	NOV		
Portugal	A	EuPCT	pending		2020	NOV		
Spain	A	EuPCT	pending		2020	NOV		
Sweden	A	EuPCT	pending		2020	NOV		
Switzerland	A	EuPCT	pending		2020	NOV		
<input type="checkbox"/> Japan	A	PCT	pending		2020	NOV		
<input type="checkbox"/> USA	A		pending		2020	NOV		

Total costs 1,105
Costs until expiry 21,171

'Costs until expiry' is a rough estimate based on the data of the case which were available on the day of the print-out. It consists only of renewal fees and does not contain any other fee, such as prosecution, translation, printing fees etc. It is further important to know that in many countries renewal fees first become due after grant. These potential renewal fees are not contained in the 'Costs until expiry'. In the European patent procedure renewal fees have to be paid centrally for the pending European patent application only. As soon as the grant has taken place, renewal fees will be due for each European designation individually. Such potential renewal fees are not contained in the 'Costs until expiry' if the European patent application is pending on the date of the print-out.

Patsys

Decision List
for abandonment

Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CL/V -30880/CGV 2112

No Decision

Country	Ident. code	Fil.proc.	Remarks
PCT	A	PCT	End of internat. phase 2001
USA	P1		abandoned 2000
USA	P1/PROV		expired 2000

Examination

Country	Ident. code	Fil.proc.	Due date
Japan	A	PCT	28.03.2007

Decision date:

Signature:
(according to section regulations)

Intellectual Property Steering Committee (IPSC) View

CIBA Vision Corporation

U.S. Patent No. U.S. Issue Date : U.S. Exp. Date : Inventor 1 : Hirt, Thomas Inventor 2 : Schremmer, Jackie Inventor 3 : Holland, Troy	Related Products : Related Projects/Materials : XXXXXX U.S. Case Number : CGV 2112 Basel Case Number : CL/V-30880P1
-------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------

U.S. Title : Organic Compounds

U.S. Abstract: The invention relates to novel crosslinkable copolymers of formula (see specification for structure) wherein the variables are as defined in the claims. The copolymers of the invention are especially useful for the manufacture of biomedical moldings, for example ophthalmic moldings such as in particular contact lenses.

U.S. Broad Claims: 1. An amphiphilic block copolymer of formula (see specification for structure) wherein A is a hydrophobic polysiloxane or perfluoroalkyl polyether segment; B is a surface-modifying hydrophilic segment having a weight average molecular weight of 100 that is devoid of a crosslinkable group; Q is a moiety comprising at least one crosslinkable ethylenically unsaturated group; (alk) is C2-C20-alkylene which is unsubstituted or substituted by hydroxy; L1, L2 and L3 are each independently of the other a linking group; p1 and q1 are each independently of the other an integer from 1 to 12; and either t is 0 and p and q are each independently of the other an integer from 1 to 25; or t is an integer from 1 to 8 and p and q are each 0.

Latest IPSC Comments: June 2003 IPSC Comments: MAINTAIN. (JWC)

Miscellaneous: Dangling chains

Decision List for abandonment

TE3

28.04.2005
Page 64/147

Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CL/V -30880/CGV 2112

Priority 30.03.1999 USA
Attorney RKM
Section Subgroup LNS
Inventor(s) T. Hirt J. Schremmer
T. Holland D. Lohmann
Contracts 99/02/ Contract active maint. relevant

Short description of the invention

BULK MATERIAL WITH WETTABLE SURFACE
WITHOUT COATING; DANGLING CHAINS

Products, compounds, projects

Invention category Product

☐ Case abandonment world-wide

Decision to abandon

Country	Ident. code	Fil.proc.	Status	Fee due	Expiry	Owner	Fee ind.	Costs CHF
<input type="checkbox"/> France	A	EuPCT	granted	03/2006	2020	NOV	7	208
<input type="checkbox"/> Germany	A	EuPCT	granted	03/2006	2020	NOV	7	277
<input type="checkbox"/> Great Britain	A	EuPCT	granted	03/2006	2020	NOV	7	204
<input type="checkbox"/> Italy	A	EuPCT	granted	03/2006	2020	NOV	7	198
<input type="checkbox"/> Japan	A	PCT	pending		2020	NOV		
<input type="checkbox"/> USA	A		pending		2020	NOV		

Total costs 887

Costs until expiry 44,234

'Costs until expiry' is a rough estimate based on the data of the case which were available on the day of the print-out. It consists only of renewal fees and does not contain any other fee, such as prosecution, translation, printing fees etc. It is further important to know that in many countries renewal fees first become due after grant. These potential renewal fees are not contained in the 'Costs until expiry'. In the European patent procedure renewal fees have to be paid centrally for the pending European patent application only. As soon as the grant has taken place, renewal fees will be due for each European designation individually. Such potential renewal fees are not contained in the 'Costs until expiry' if the European patent application is pending on the date of the print-out.

No Decision

Country	Ident. code	Fil.proc.	Remarks
PCT	A	PCT	End of internat. phase 2001
USA	P1		abandoned 2000
USA	P1/PROV		expired 2000

Examination

Country	Ident. code	Fil.proc.	Due date
Japan	A	PCT	28.03.2007

Decision List
for abandonment


Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CL/V -30880/CGV 2112

Decision date:

Signature:
(according to section regulations)

**Intellectual Property Steering Committee (IPSC) View
CIBA Vision Corporation**

U.S. Patent No. U.S. Issue Date : U.S. Exp. Date : Inventor 1 : Hirt, Thomas Inventor 2 : Schremmer, Jackie Inventor 3 : Holland, Troy	Related Products : Related Projects/Materials :  U.S. Case Number : CGV 2112 Basel Case Number : CL/V-30880P1
-------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

U.S. Title : Organic Compounds

U.S. Abstract: The invention relates to novel crosslinkable copolymers of formula (see specification for structure) wherein the variables are as defined in the claims. The copolymers of the invention are especially useful for the manufacture of biomedical moldings, for example ophthalmic moldings such as in particular contact lenses.

U.S. Broad Claims: 1. An amphiphilic block copolymer of formula (see specification for structure) wherein A is a hydrophobic polysiloxane or perfluoroalkyl polyether segment; B is a surface-modifying hydrophilic segment having a weight average molecular weight of 100 that is devoid of a crosslinkable group; Q is a moiety comprising at least one crosslinkable ethylenically unsaturated group; (alk) is C2-C20-alkylene which is unsubstituted or substituted by hydroxy; L1, L2 and L3 are each independently of the other a linking group; p1 and q1 are each independently of the other an integer from 1 to 12; and either t is 0 and p and q are each independently of the other an integer from 1 to 25; or t is an integer from 1 to 8 and p and q are each 0.

Latest IPSC Comments: 06/02/2004 - MAINTAIN LNS B6
June 2003 IPSC Comments: MAINTAIN. (JWC)

Miscellaneous: Dangling chains

Decision List
for abandonment

E4

Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CLV -30880/CGV 2112

Priority 30.03.1999 USA
Attorney RKM
Section Subgroup LNS
Inventor(s) T. Hirt J. Schremmer
T. Holland D. Lohmann
Contracts 99/02/ Contract active maint. relevant

Short description of the invention
BULK MATERIAL WITH WETTABLE SURFACE
WITHOUT COATING; DANGLING CHAINS

Products, compounds, projects


Invention category Product

☐ Case abandonment world-wide

Decision to abandon

Country	Ident. code	Fil.proc.	Status	Fee due	Expiry	Owner	Fee ind.	Costs CHF
<input type="checkbox"/> France	A	EuPCT	granted	03/2007	2020	NOV	8	209
<input type="checkbox"/> Germany	A	EuPCT	granted	03/2007	2020	NOV	8	372
<input type="checkbox"/> Great Britain	A	EuPCT	granted	03/2007	2020	NOV	8	248
<input type="checkbox"/> Italy	A	EuPCT	granted	03/2007	2020	NOV	8	272
<input type="checkbox"/> Japan	A	PCT	pending		2020	NOV		
<input type="checkbox"/> USA	A		pending		2020	NOV		

Total costs 1,101
Costs until expiry 43,879

'Costs until expiry' is a rough estimate based on the data of the case which were available on the day of the print-out. It consists only of renewal fees and does not contain any other fee, such as prosecution, translation, printing fees etc. It is further important to know that in many countries renewal fees first become due after grant. These potential renewal fees are not contained in the 'Costs until expiry'. In the European patent procedure renewal fees have to be paid centrally for the pending European patent application only. As soon as the grant has taken place, renewal fees will be due for each European designation individually. Such potential renewal fees are not contained in the 'Costs until expiry' if the European patent application is pending on the date of the print-out.

No Decision

Country	Ident. code	Fil.proc.	Remarks
PCT	A	PCT	End of internat. phase 2001
USA	P1		abandoned 2000
USA	P1/PROV		expired 2000

Examination

Country	Ident. code	Fil.proc.	Due date
Japan	A	PCT	28.03.2007

Patsys

Decision List
for abandonment

Section CIBA Vision, Prio JAN-MAR, Cost code = CL

CL/V -30880/CGV 2112

Decision date:

Signature:
(according to section regulations)

**Intellectual Property Steering Committee (IPSC) View
CIBA Vision Corporation**

U.S. Patent No. U.S. Issue Date : U.S. Exp. Date : Inventor 1 : Hirt, Thomas Inventor 2 : Schremmer, Jackie Inventor 3 : Holland, Troy	Related Products : Related Projects/Materials : [REDACTED] U.S. Case Number : CGV 2112 Basel Case Number : CL/V-30880PI
-------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------

U.S. Title : Organic Compounds

U.S. Abstract: The invention relates to novel crosslinkable copolymers of formula (see specification for structure)
wherein the variables are as defined in the claims. The copolymers of the invention are especially useful for the manufacture of biomedical moldings, for example ophthalmic moldings such as in particular contact lenses.

U.S. Broad Claims: 1. An amphiphilic block copolymer of formula (see specification for structure) wherein A is a hydrophobic polysiloxane or perfluoroalkyl polyether segment; B is a surface-modifying hydrophilic segment having a weight average molecular weight of 100 that is devoid of a crosslinkable group; Q is a moiety comprising at least one crosslinkable ethylenically unsaturated group; (alk) is C2-C20-alkylene which is unsubstituted or substituted by hydroxy; L1, L2 and L3 are each independently of the other a linking group; p1 and q1 are each independently of the other an integer from 1 to 12; and either t is 0 and p and q are each independently of the other an integer from 1 to 25; or t is an integer from 1 to 8 and p and q are each 0.

Latest IPSC Comments: May 25, 2005 IPSC Comments: Maintain (JWC). 06/02/2004 - MAINTAIN LNS B6

June 2003 IPSC Comments: MAINTAIN. (JWC)

Miscellaneous: Dangling chains

PATENT DECISION LIST

14 - May - 2007

Family 30880

Original Reference **CGV 2112** Keywords **Silicone Containing**
BULK MATERIAL WITH WETTABLE SURFACE WITHOUT COATING; DANGLING CHAINS

Internal Title

Business Unit **CV** Global Attorney **Zhou (JZ)**
 Business Line **CL** EP Attorney **Bielefeldt (FB)**
 Invention Category **Material** US Attorney **Zhou (JZ)**

Inventors **Hirt Thomas**
Schremmer Jacalyn Mary
Holland Troy Vernon
Lohmann Dieter

First Priority **United States Of America (NP) - 30 Mar 1999 - 09/280510**

Fees Due

Country	Status	Past costs CHF	Next annuity	Cost CHF	Cost until expiry CHF
CL/V -30880A/CGV FR-EPT France	Grant	1,313	31-MAR-2006 for 07	244	8,043
CL/V -30880A/CGV DE-EPT Germany	Grant	4,243	31-MAR-2006 for 07	292	20,425
CL/V -30880A/CGV GB-EPT United Kingdom	Grant	642	28-MAR-2008 for 09	317	7,293
Total :		6,198		853	35,761

In Force - No fees due

Country	Status
CL/V -30880A/CGV IT-EPT Italy	Grant
CL/V -30880A/CGV JP-PCT Japan	Publication of application
CL/V -30880A/CGV US-NP United States Of America	Filed

Abandoned - not in force

Country	Status
CL/V -30880A/CGV WO-PCT International Procedure	Abandoned
CL/V -30880/P1/CGV US-NP United States Of America	Abandoned Priority Application
CL/V -30880/P1/PROV/CGV US-PSP United States Of America	Terminated

**Intellectual Property Steering Committee (IPSC) View
CIBA Vision Corporation**

U.S. Patent No. U.S. Issue Date : U.S. Exp. Date : Inventor 1 : Hirt, Thomas Inventor 2 : Schremmer, Jackie Inventor 3 : Holland, Troy	Related Products : Related Projects/Materials : XXXXXXXXXX U.S. Case Number : CGV 2112 Basel Case Number : CL/V-30880P1
-------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

U.S. Title : Organic Compounds

U.S. Abstract: The invention relates to novel crosslinkable copolymers of formula (see specification for structure)
 wherein the variables are as defined in the claims. The copolymers of the invention are especially useful for the manufacture of biomedical moldings, for example ophthalmic moldings such as in particular contact lenses.

U.S. Broad Claims: 1. An amphiphilic block copolymer of formula (see specification for structure) wherein A is a hydrophobic polysiloxane or perfluoroalkyl polyether segment;
 B is a surface-modifying hydrophilic segment having a weight average molecular weight of 100 that is devoid of a crosslinkable group;
 Q is a moiety comprising at least one crosslinkable ethylenically unsaturated group;
 (alk) is C2-C20-alkylene which is unsubstituted or substituted by hydroxy;
 L1, L2 and L3 are each independently of the other a linking group;
 p1 and q1 are each independently of the other an integer from 1 to 12; and either
 t is 0 and p and q are each independently of the other an integer from 1 to 25; or
 t is an integer from 1 to 8 and p and q are each 0.

Latest IPSC Comments: May 25, 2005 IPSC Comments: Maintain (JWC). 06/02/2004 - MAINTAIN
LNS B6
June 2003 IPSC Comments: MAINTAIN. (JWC)

Miscellaneous: Dangling chains

CIBAVision®

A Novartis Company

CIBA Vision Corporation

Patent Department

11460 Johns Creek Parkway

Duluth, GA 30097-1556

Change filing receipt

F1

FAX MESSAGE

DATE: May 3, 2000

TO: Betty Robinson
US PTO

FROM: Ann Brayley
CIBA Vision Patent Department
Voice: 678-415-3672 Fax: 678-415-3068

Dear Ms. Robinson,

Please see attachment. Our Docket CL/V-30880/P1/CGV2112 carries an application number of 09/280,510, (as indicated on the Filing Receipt) not 09/208,510. Please send a corrected Decision on Petition.

Thank you.

TOTAL NUMBER OF PAGES (including coversheet) 2

The information contained in this facsimile message is legally privileged and confidential information, intended only for use by the addressee listed above. If you have received this message in error, you are hereby notified that any disseminating, distributing or copying of this information is strictly prohibited. Further, if you have received this information in error, we request that you contact Ann Brayley 770-418-3672. We appreciate your cooperation.


April 11, 2000

103-305 9822

Page # 4

Melvyn M Kassenoff
Novartis-Corporation
Patent and Trademark Dept
564 Morris Avenue
Summit, NJ 07904-1027

RJG



In re Application of:
Hirt, et al.

Application No.: 09/208,510

Filed: March 30, 1999

Attorney Docket No.: CLV-30880/P1CGV2112

DECISION ON PETITION


This is a decision on your petition received in the Patent and Trademark Office on March 13, 2000 treated as a petition under 37 CFR 1.53(b)(2)(ii) to convert the above identified application to a Provisional application under 35 U.S.C. 111 (b) and 37 CFR 1.53(b)(2).

The petition is granted.

The application will be processed in the Office of Initial Patent Examination (OIPE) as a Provisional application under 35 U.S.C. 111(b) and 37 CFR 1.53(b)(2), including the assignment of a new Provisional application number.

The Provisional application serial number is 60/183,047 the filing receipt for the Provisional application number will be communicated to applicant by OIPE in due course.

Betty L. Robinson, Program Assistant
Office of Initial Patent Examination
(703) 308-0910



APRIL 20, 2000

Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

Your Ref.

CIBA Vision Corporation
Our Ref. Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:
PRD V

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880/P1 CVG2112
Application No. 09/208,510

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase



- ☒ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)



Very truly yours,

Robert J. Gorman

Robert J. Gorman
678-415-4389

Please note that the
correct Application-
Nr. is 09/280510 and
not 09/208510!

Regards

Frau T. Oswald
Patent & Trademarks
S - 503.703-04-55 31

T. Oswald

April 11, 2000


103-385 9822

Washington, D.C. 20231

Page # 4

Melvyn M Kassenoff
Novartis Corporation
Patent and Trademark Dept
564 Morris Avenue
Summit, NJ 07904-1027

RJG



In re Application of:
Hirt, etal.

Application No.: 09/208,510 —

Filed: March 30, 1999

Attorney Docket No.: CLV-30880/P1CGV2112

DECISION ON PETITION


This is a decision on your petition received in the Patent and Trademark Office on March 13, 2000 treated as a petition under 37 CFR 1.53(b)(2)(ii) to convert the above identified application to a Provisional application under 35 U.S.C. 111 (b) and 37 CFR 1.53(b)(2).

The petition is granted.

The application will be processed in the Office of Initial Patent Examination (OIPE) as a Provisional application under 35 U.S.C. 111(b) and 37 CFR 1.53(b)(2), including the assignment of a new Provisional application number.

The Provisional application serial number is 60/183,047 the filing receipt for the Provisional application number will be communicated to applicant by OIPE in due course.

Betty L. Robinson, Program Assistant
Office of Initial Patent Examination
(703) 308-0910



- 7. Mai 1999

Patent Department
Telephone: 770-418-3672
Fax: 770-418-3068

APPL.	M/D	F/L	PS/TS	
Kopien:				

April 27, 1999

DUE DATE:

Dr. J. Dietz
Novartis Services AG
Patent and Trademark Dept.
Lichtstrasse 35
CH-4002 Basel


Re: Patent Application
Application No.: 09/280,510
Case: CL/V-30880/P1/CGV2112

Ladies and Gentlemen:

To keep you advised of the prosecution of the above-indicated case, we are enclosing

- () copy of Blue Filing Receipt -
- () copy of Application Transmittal Letter, Specification, Drawings, Basel casecard, Diskette
- () copy of Conversion of Non-provisional to Provisional Application Transmittal
- () copy of PTO Form 903 - Notification of Acceptance of Application (PCT)
- (x) copy of Post Card received from PTO
- () copy of 1A Assignment and Transmittal
- () copy of Notice of Allowance and Issue Fee Due w/supporting documents & allowed claims
- () copy of Issue Fee as submitted to PTO
- () copy of Amendment dated 4/19/99
- () copy of Petition for Extension of Time
- () copy of Notice of Appeal dated
- () copy of Office action dated
- () copy of Information Disclosure Transmittal with PTO Form 1449 only
- () copy of Notice of Missing Parts
- () copy of Response to Notice of Missing Parts
- () copy of Claim of Priority, dated
- () copy of other:

NOVARTIS CORPORATION



Ann Brayley
Patent Administrative Assistant

Case No. CGV 2112

Application/Serial No. _____

Filing Date: 3/30/99

Due Date: 011123456789101112131415161718192021222324252627282930

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of receipt of the items checked below:

- ☐ Amendment - Fee \$ APP 1999
- ☐ Appeal Brief - Fee \$ 3/60
- ☒ Application Filing Papers - Fee \$ 450
- ☐ PCT national stage entry
- ☐ Provisional Application

- ☐ Assignment Recommendation - Fee \$ JC640 U.S. PTO
- ☐ Associate Power of Attorney - Fee \$ 09/280510
- ☐ Claim of Priority

- ☐ Certified Copies
- ☒ Declaration and Power of Attorney - Fee \$ 03/30/99

- ☐ Declaration ☐ Rule 131 ☐ Rule 132
- ☐ Foreign Filing license request

- ☐ Formal Drawings

- ☐ Information Disclosure Statement - Fee \$ _____

- ☐ Issue Fee Transmittal - Fee \$ _____

- ☐ Letter/Response

- ☐ Notice of Appeal - Fee \$ _____

- ☐ Petition for _____ - Fee \$ _____

- ☐ Petition for extension of time - Fee \$ _____

- ☐ Reply Brief

- ☐ Request for Oral Hearing - Fee \$ _____

- ☐ Request for Certification of Correction - Fee \$ _____

- ☐

MUL

83049A/97

21. Mai 1999

APPL.	M/D	F/L	PS/TS
-------	-----	-----	-------

Kopien:

May 19, 1999

Patent Department
Telephone: 770-418-3672
Fax: 770-418-3068

DUE DATE:

Dr. J. Dietz
Novartis Services AG
Patent and Trademark Dept.
Lichtstrasse 35
CH-4002 Basel


Re: Patent Application
Application No.: 09/280,510
Case: CLV-30880/P1/CGV2112

Ladies and Gentlemen:

To keep you advised of the prosecution of the above-indicated case, we are enclosing

- (x) copy of Blue Filing Receipt
- () copy of Application Transmittal Letter, drawings, Form 1449
- () copy of Conversion of Non-provisional to Provisional Application Transmittal
- () copy of PTO Form 903 - Notification of Acceptance of Application (PCT)
- () copy of Post Card received from PTO
- () copy of 1A Assignment and Transmittal
- () copy of Notice of Allowance and Issue Fee Due w/supporting documents & allowed claims
- () copy of Issue Fee as submitted to PTO
- () copy of Amendment dated
- () copy of Petition for Extension of Time
- () copy of Notice of Appeal dated
- () copy of Office action dated
- () copy of Information Disclosure Transmittal with PTO Form 1449 only
- () copy of Notice of Missing Parts
- () copy of Response to Notice of Missing Parts
- () copy of Claim of Priority, dated
- () copy of other:



NOVARTIS CORPORATION



Ann Brayley
Patent Administrative Assistant

J. Dietz
A. Hesse
B. Hesse
W. Schmid
G. von Spreti

25. Mai 1999

ERSTERFASSUNG	Visum:	
ZWEITERFASSUNG	Visum:	



APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/280,510	03/30/99 ✓	1714	\$760.00	CGV2112	0	17	1

001095

MELVYN M KASSENOFF
NOVARTIS CORPORATION
PATENT AND TRADEMARK DEPT
564 MORRIS AVENUE
SUMMIT NJ 07901-1027

*CL/V-30880/P1/CGV2112**MUL**CV*

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)


THOMAS HIRT, ATLANTA, GA; TROY VERNON HOLLAND, SUWANNE,
GA; DIETER LOHMANN, MUNCHENSTEIN, SWITZERLAND.

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 04/15/99

TITLE

ORGANIC COMPOUNDS

PRELIMINARY CLASS: 523



DATA ENTRY BY: ROBINSON, CARMENCITA TEAM: 02 DATE: 04/15/99



(see reverse)

F2



Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

DATE: March 14, 2000

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

FOR INFORMATION
ONLY

Re: CL/V-30080/A/CGV2112
Application No.

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☒ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389

DOCKET NOTE/REPORT ENTRY

F-3

CASE CLV. 30880/A/CGV2112 APPLICATION NO. _____

PRESENT DOCKET DATE 3/29/00

☐ EXTEND TO _____

THE FOLLOWING ACTION HAS BEEN TAKEN:

<input type="checkbox"/> AMENDMENT/RESPONSE	<input type="checkbox"/> DRAWINGS
<input type="checkbox"/> RESPONSE TO FINAL REJECTION	<input type="checkbox"/> PRELIMINARY AMENDMENT
<input type="checkbox"/> INFORMATION DISCLOSURE STATEMENT <input type="checkbox"/> (LATE FEE) - \$240 <input type="checkbox"/> NO FEE	<input type="checkbox"/> SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <input type="checkbox"/> (LATE FEE) - \$240 <input type="checkbox"/> NO FEE
<input type="checkbox"/> NOTICE OF APPEAL \$300	<input type="checkbox"/> ISSUE FEE \$1210
<input type="checkbox"/> APPEAL BRIEF \$300	<input type="checkbox"/> PTO-1449 FORM
<input type="checkbox"/> ASSIGNMENT RECORDATION \$40	<input type="checkbox"/> DIVISION CHECK
<input type="checkbox"/> CLAIM OF PRIORITY	<input type="checkbox"/> REQUEST FOR CORRECTED FILING RECEIPT
<input type="checkbox"/> DECLARATION - MISSING PARTS/MISSING REQUIREMENTS \$130	<input type="checkbox"/> REQUEST FOR CERTIFICATE OF CORRECTION
<input type="checkbox"/> EXTENSIONS OF TIME <input type="checkbox"/> 1 st - 110 <input type="checkbox"/> 2 nd - \$380 <input type="checkbox"/> 3 rd - \$870 <input type="checkbox"/>	
<input checked="" type="checkbox"/> APPLICATION*	<input type="checkbox"/> PCT <input type="checkbox"/> PROVISIONAL - \$150 <input type="checkbox"/> PETITION TO CONVERT - \$50
FEE \$ <u>7600</u> <input type="checkbox"/> CIP <input type="checkbox"/> CONTINUATION <input type="checkbox"/> DIVISIONAL <input type="checkbox"/> FILED "A" (Old "R")	

OTHER _____

ATTORNEY: RJG | DATE: 3/14/00

* WITH BASLE FAX (On U.S. Originated Case Only)

FAXED _____



Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

DATE: March 29, 2000

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556



Re: CL/V-30880/A/CGV2112
Application No. 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☒ Other Document(s) Serial Card

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389

F5



Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

DATE: May 31, 2000

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880/A/CGV2112
Application No. 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☒ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389

DOCKET NOTE/REPORT ENTRY

F6

CASE CL/V. 30880/A/CGV2112APPLICATION NO. 09/0
525, 158PRESENT DOCKET DATE 7/16/00☐ EXTEND TO _____THE FOLLOWING ACTION HAS BEEN TAKEN:☐ AMENDMENT/RESPONSE☐ DRAWINGS☐ RESPONSE TO FINAL REJECTION☐ PRELIMINARY AMENDMENT☐ INFORMATION DISCLOSURE
STATEMENT☐ SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT☐ (LATE FEE) - \$240☐ NO FEE☐ (LATE FEE) - \$240☐ NO FEE☐ NOTICE OF APPEAL

\$300

☐ ISSUE FEE

\$1210

☐ APPEAL BRIEF

\$300

☐ PTO-1449 FORM☐ ASSIGNMENT RECORDATION

\$40

☐ DIVISION CHECK☐ CLAIM OF PRIORITY☐ REQUEST FOR CORRECTED FILING
RECEIPT☒ DECLARATION -
MISSING PARTS/MISSING REQUIREMENTS

\$130

☐ REQUEST FOR CERTIFICATE OF
CORRECTION☐ EXTENSIONS OF TIME☐ 1st - 110☐ 2nd - \$380☐ 3rd - \$870☐☐ APPLICATION*☐ PCT☐ PROVISIONAL - \$150☐ PETITION TO CONVERT - \$50FEE \$ _____ ☐ CIP ☐ CONTINUATION ☐ DIVISIONAL ☐ FILED "A"
(Old "R")

OTHER _____

ATTORNEY: R J G | DATE: 6/7/00

* WITH BASLE FAX (On U.S. Originated Case Only)

FAXED _____

F7



Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

DATE: June 13, 2000

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880/CGV2112
Application No. 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☒ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389

F8



Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

DATE: July 14, 2000

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880/A/CGV2112
Application No. 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☒ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389



Dr. Bernd Liphardt
Patent Attorney

Novartis AG
Corporate Intellectual Property
Patent & Trademark Department CH
CH-4002 Basel
Switzerland
Tel: +41 61 324 34 95
Fax: +41 61 322 75 32

F9

CIBA Vision Corporation
Attn. Mr. Rob Gorman
11460 Johns Creek Parkway
Duluth / Atlanta, GA 30155

June 27, 2000

Your Ref:

Our Ref:
LIP


Information Disclosure Statement

U.S. Patent Application No: 09/525,158
Case: CL/V-30880/CGV 2112

Ladies and Gentlemen

I. References (and English language equivalents thereof)

- [1] US-A-5,219,965 (Valinth Jr et al.)
- [2] US-A-5,364,918 (Valinth Jr et al.)
- [3] US-A-5,589,563 (Ward et al.)



II. Related pending U.S. Patent Applications

U.S. Serial No. 09/217,238 , our Case CL/V-30764/A/CGV 2066

Please find enclosed herewith:

- ☒ copy of the references mentioned above and English language equivalents or abstracts thereof

Yours faithfully
Novartis AG

Dr. Bernd Liphardt
Patent Attorney

Dr. Jörg Dietz
Head of Patents CIBA Vision, Consumer
Health, Animal Health

CIBA Vision Corporation
Attn. Mr. Rob Gorman
11460 Johns Creek Parkway
Duluth / Atlanta, GA 30155

TELEFAX

From: +41 61 322 75 32
To: 0001 678 415 3068
Total pages: 1

June 30, 2000

Your Ref:

Our Ref:
LIP

Information Disclosure Statement

U.S. Patent Application No: 09/525,158
Case: CL/V-30880/A/CGV 2112

Ladies and Gentlemen

1. References (and English language equivalents thereof)

- [1] WO-A-97/00274 (our Case CL/V-20486/A/ERT 7
- [2] EP-A-291,452 (equivalent to [3], our case CL/V-16453/+CGV 1274)
- [3] US-A-4,837,289 (Mueller et al.), equivalent to [2])
- [4] US-A-5,760,100 (Nicolsòn et al.) (CL/V-20676/P1/CGV 1764, JUMP)
- [5] WO-A-97/49740 (CL/V-20926/A/CGV 1866)
- [6] WO-A-96/31791 (CL/V-20395/A, Betacon)
- [7] EP-A-330,616 (CL/V-16918/+CGV 1332)

Please find enclosed herewith:

- ☒ copy of the references (by confirmation mail)
- ☒ copy of PCT/EP Search Report showing date of the Report (by conf. mail)
- ☒ copy of equivalency list issued by the EPO

Yours faithfully
Novartis AG



Dr. Bernd Liphardt
Patent Attorney



Dr. Jörg Dietz
Head of Patents CIBA Vision, Consumer
Health, Animal Health

F11

CASE CC/V-30880/A/CGV2112 APPLICATION NO. _____

PRESENT DOCKET DATE 6/14/00

☐ EXTEND TO _____

THE FOLLOWING ACTION HAS BEEN TAKEN:

<input type="checkbox"/> AMENDMENT/RESPONSE	<input type="checkbox"/> DRAWINGS
<input type="checkbox"/> RESPONSE TO FINAL REJECTION	<input type="checkbox"/> PRELIMINARY AMENDMENT
<input checked="" type="checkbox"/> INFORMATION DISCLOSURE STATEMENT	<input type="checkbox"/> SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
<input type="checkbox"/> (LATE FEE) - \$240 <input type="checkbox"/> NO FEE	<input type="checkbox"/> (LATE FEE) - \$240 <input type="checkbox"/> NO FEE
<input type="checkbox"/> NOTICE OF APPEAL \$300	<input type="checkbox"/> ISSUE FEE \$1210
<input type="checkbox"/> APPEAL BRIEF \$300	<input type="checkbox"/> PTO-1449 FORM
<input type="checkbox"/> ASSIGNMENT RECORDATION \$40	<input type="checkbox"/> DIVISION CHECK
<input type="checkbox"/> CLAIM OF PRIORITY	<input type="checkbox"/> REQUEST FOR CORRECTED FILING RECEIPT
<input type="checkbox"/> DECLARATION - MISSING PARTS/MISSING REQUIREMENTS \$130	<input type="checkbox"/> REQUEST FOR CERTIFICATE OF CORRECTION
<input type="checkbox"/> EXTENSIONS OF TIME	
<input type="checkbox"/> 1 st - 110 <input type="checkbox"/> 2 nd - \$380 <input type="checkbox"/> 3 rd - \$870 <input type="checkbox"/>	
<input type="checkbox"/> APPLICATION* <input type="checkbox"/> PCT <input type="checkbox"/> PROVISIONAL - \$150 <input type="checkbox"/> PETITION TO CONVERT - \$500	

FEE \$ _____ ☐ CIP ☐ CONTINUATION ☐ DIVISIONAL ☐ FILED "A" (Old "R")

OTHER _____

ATTORNEY: RTG | DATE: 8/30/00

* WITH BASLE FAX (On U.S. Originated Case Only)

FAXED _____

F12



Novartis AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

DATE: August 31, 2000

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880A/CGV2112
Application No. 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☒ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
678-415-4389

F13

Memorandum



A Novartis Company

Date: March 28, 2001

To: Jackie Schremmer

From: Rob Gorman

Patent Attorney
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097
rob.gorman@cibavision.novartis.com
phone 678 415-4389
fax 678-415-3018

Subject: CL/V-30880A/CGV2112
Serial No. 09/525,158

We have received a response from the U.S. Patent and Trademark Office (an "Office action") in the above-identified patent application which names you as an inventor. A copy of this Office action is enclosed for your review.

We are sending you a copy of this Office action for two reasons. First, we wish to keep you informed of the progress in your case. Second, we wish to have your input on the differences between your invention (as defined by the claims) and the prior art (other patents and publications) used against us by the Patent Examiner.

We also wish to remind you of the CONTINUING DUTY to inform the Patent Office of any prior art references (patents, publications, etc.) which may be deemed relevant to the patentability of the claimed invention in the pending patent application. PLEASE SEND US COPIES OF ANY POTENTIALLY RELEVANT PRIOR ART WHICH YOU HAVE NOT ALREADY SENT.

With respect to your comments in distinguishing the prior art, please focus on the rejections in the Office action which discuss 35 U.S.C. 102 (novelty) and 35 U.S.C. 103 (obviousness). If you have any questions, or would like to discuss the differences between your invention and the prior art, please call.

In order to meet the deadline for responding to this Office Action, we need to have your comments by **May 1, 2001**.

Thank you for your assistance.

F14



Novartis Pharma AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

DATE: March 28, 2001

Your Ref.

CIBA Vision Corporation
Legal Department
11460 John Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE: June 12, 2001

RESPONSE DATE:

FOR INFORMATION ONLY

Re: CL/V-30880A/CGV2112
Application No.: 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☒ Paper(s) received from the PTO (Dated: 3/12/01)
- ☐ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Rob Gorman
(Signature)

Robert J. Gorman, Jr.
678-415-4389



Dr. Bernd Liphardt
Patent Attorney

Novartis AG
Corporate Intellectual Property
Patent & Trademark Department CH
CH-4002 Basel
Switzerland
Tel: +41 61 324 79 97
Fax: +41 61 322 75 32

F15

CIBA Vision Corporation
Attn. Mr. Rob Gorman
11460 Johns Creek Parkway
Duluth / Atlanta, GA 30155


TELEFAX

From: +41 61 322 75 32
To: 0001 678 415 3068

Total pages: 2

Your Ref:

May 22, 2001



U.S. Patent Application Serial No. 09/525,158 – Case CL/V-30880A/CGV2112

Dear Rob

Thank you for your letter of March 28, 2001 with the enclosed Office action.
Please find below our comments and proposals.

Regarding the restriction requirement under 35 U.S.C. 121, we agree to confirm the election of group I (claims 1 to 12).

Specification

- The terms (alk) and (alk') are different and relate to different formulas. (alk) (page 1, line 25) relates to formula (1), whereas (alk') (page 3, line 2) relates to formula 2. Accordingly, no amendment is deemed necessary.
- If acceptable under US practice, we suggest deleting the word "suitable" in the expression "a suitable salt" (page 9, lines 2-3).
- Please add the missing hydrogens in "₃C" in line 5 of page 37.

Claim Objections

- In our view claim 4 is a perfect dependent claim. However, if there are rules or provisions we are unaware of, please feel free to rewrite the claim in independent form.
- As to claim 7 we propose to amend it as follows:
"An amphiphilic block copolymer according to claim 1, wherein B is a non-ionic segment selected from the group consisting of a polyoxyalkylene, polysaccharide, polypeptide, poly(vinylpyrrolidone), polyalkylacrylate, polymethacrylate, polyhydroxyalkylacrylate,

- polyhydroxymethacrylate, polyacyl alkylene imine, polyacryl amide, polyvinyl alcohol, polyvinyl ether and a polyol, or B is a polyionic segment selected from the group consisting of a polyallylammonium, polyethylencimine, polyvinylbenzyltrimethylammonium, polyaniline, sulfonated polyaniline, polypyrrole, polypyridine, polyacrylic acid, polymethacrylic acid, a polythiophene-acetic acid, a polystyrenesulfonic acid and a zwitterionic segment, or a salt thereof."
- Please deal with the additional informalities ("-NR-" in line 29 of claim 10 and "H (or CH₃" in claim 10 as proposed by the Examiner.

Regarding the claim rejections under 35 USC § 112:

- In the above-redrafted claim 7 the expression "a suitable salt" has been amended to "a salt" and the problems associated with the Markush language have been dealt with.
- In Claims 9 and 11 delete the phrase "for example".

As to the claim rejections under 35 USC § 102 we suggest to amend the second last line of claim 1 to

"t is 0 and p and q are each independently of the other an integer from 2 to 20; or", support for which can be found on page 2, line 20 of the specification.

The amendment is deemed to establish novelty over Meijs (US 5,981,615).

Yours very truly
Novartis AG



Dr. Bernd Liphardt
Patent AttorneyPatent Attorney



Dr. Jörg Dietz
Head of Patents CIBA Vision, Consumer Health,
Animal Health

filed 6-8-01

DOCKET NOTE/REPORT ENTRY

F16

CASE CL/V-30880A/CGV2112 APPLICATION NO. 09/525,158

PRESENT DOCKET DATE June 12, 2001

☐ EXTEND TO _____

THE FOLLOWING ACTION HAS BEEN TAKEN:

☒ AMENDMENT/RESPONSE

☐ DRAWINGS

☐ RESPONSE TO FINAL REJECTION

☐ PRELIMINARY AMENDMENT

☐ INFORMATION DISCLOSURE
STATEMENT

☐ SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

☐ (LATE FEE) - \$180

☐ NO FEE

☐ (LATE FEE) - \$180

☐ NO FEE

☐ NOTICE OF APPEAL

\$310

☐ ISSUE FEE

\$1240

☐ APPEAL BRIEF

\$310

☐ PTO-1449 FORM

☐ ASSIGNMENT RECORDATION

\$40

☐ DIVISION CHECK

☐ CLAIM OF PRIORITY

☐ REQUEST FOR CORRECTED FILING
RECEIPT

☐ DECLARATION -
MISSING PARTS/MISSING REQUIREMENTS

\$130

☐ REQUEST FOR CERTIFICATE OF
CORRECTION

☐ EXTENSIONS OF TIME

☐ 1st - 110

☐ 2nd - \$390

☐ 3rd - \$890

☐

☐ APPLICATION*

☐ PCT

☐ PROVISIONAL - \$150

☐ PETITION TO CONVERT - \$50

FEE \$ _____ ☐ CIP ☐ CONTINUATION ☐ DIVISIONAL ☐ FILED "A"
(Old "R")

OTHER _____

ATTORNEY: Richard Gershon DATE: 6-8-01

* WITH BASLE FAX (On U.S. Originated Case Only)

F17

Novartis Pharma AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

June 11, 2001

**CIBA
Vision®**
A Novartis Company

Your Ref

Our Ref CIBA Vision Corporation
Legal Department

DUE DATE:

June 10, 2001

RESPONSE DATE:

11460 Johns Creek Parkway
Atlanta, Georgia 30343-1556
FOR INFORMATION ONLY

Re: CL/V-30880/A/CGV2112

Application No: 09/ 525, 158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☒ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)

Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,

Robert J. Gorman, Jr.
Robert J. Gorman, Jr.
678-415-4389

DOCKET NOTE/REPORT ENT.

F18

CASE CH/V- 300801A/CV 2112

APPLICATION NO. 09/525, 158

PRESENT DOCKET DATE July 21, 2001

☐ EXTEND TO _____

THE FOLLOWING ACTION HAS BEEN TAKEN:

<input checked="" type="checkbox"/> AMENDMENT/RESPONSE	<input type="checkbox"/> DRAWINGS
<input type="checkbox"/> RESPONSE TO FINAL REJECTION	<input type="checkbox"/> PRELIMINARY AMENDMENT
<input type="checkbox"/> INFORMATION DISCLOSURE STATEMENT	<input type="checkbox"/> SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
<input type="checkbox"/> (LATE FEE) - \$180 <input type="checkbox"/> NO FEE	<input type="checkbox"/> (LATE FEE) - \$180 <input type="checkbox"/> NO FEE
<input type="checkbox"/> NOTICE OF APPEAL \$310	<input type="checkbox"/> ISSUE FEE \$1240
<input type="checkbox"/> APPEAL BRIEF \$310	<input type="checkbox"/> PTO-1449 FORM
<input type="checkbox"/> ASSIGNMENT RECORDATION \$40	<input type="checkbox"/> DIVISION CHECK
<input type="checkbox"/> CLAIM OF PRIORITY	<input type="checkbox"/> REQUEST FOR CORRECTED FILING RECEIPT
<input type="checkbox"/> DECLARATION - MISSING PARTS/MISSING REQUIREMENTS \$130	<input type="checkbox"/> REQUEST FOR CERTIFICATE OF CORRECTION

☐ EXTENSIONS OF TIME

☐ 1st - 110 ☐ 2nd - \$390 ☐ 3rd - \$890 ☐

☐ APPLICATION* ☐ PCT ☐ PROVISIONAL - \$150 ☐ PETITION TO CONVERT - \$50

FEE \$ no fee ☐ CIP ☐ CONTINUATION ☐ DIVISIONAL ☐ FILED "A" (Old "R")

OTHER _____

ATTORNEY: Jian Zhou | DATE: July 3, 2001

Novartis Pharma AG
Patent & Trademark Department
CH-4002 Basel, Switzerland

DATE: July 25, 2001

Your Ref.

CIBA Vision Corporation
Legal Department
11460 Johns Creek Parkway
Duluth, Georgia 30097-1556

DUE DATE:

RESPONSE DATE:

**FOR INFORMATION
ONLY**

Re: CL/V-30880A/CGV2112
Application No.: 09/525,158

Ladies and Gentlemen:

Enclosed are copies of the following:

Filing Phase

- ☐ Regular Application filed as a Priority Application
- ☐ Provisional Application filed as a Priority Application
- ☐ Petition to Convert Regular Application into a Provisional Application
- ☐ Regular Application Based On Provisional Application(s) and/or Foreign Application(s)
- ☐ CPA Transmittal Form
- ☐ Continuation of Application No. _____
- ☐ Division of Application No. _____
- ☐ Continuation-in-part of Application No. _____
- ☐ Entry of PCT Application Into National Stage
- ☐ Official Filing Receipt
- ☐ Other Document(s)

Prosecution Phase

- ☐ Paper(s) received from the PTO (Dated: _____)
- ☒ Paper(s) sent to the PTO (amendment)
- ☐ Other Document(s)


Issuance

- ☐ Notice of Allowance (Dated: _____)
- ☐ Issue Notification Form
- ☐ Issue Fee Transmittal Slip
- ☐ Patent (three soft copies)
- ☐ Other Document(s)

Miscellaneous

- ☐ Notice of Abandonment (Dated: _____)
- ☐ Assignment
- ☐ Assignment Recordation Cover Sheet
- ☐ Other Document(s)

Very truly yours,


Jian Zhou
678-415-4691

Filed
5.10.02

Docket Note / Report Entry

Case No.: CLV-30880/A/C6V2112 Application No.: 09/525,158

Present Docket Date: June 5, 2002

☐ Extend To: / /

F20

The Following Action Has Been Taken:

- | | | | |
|---------------------------------------------------------------------|---------------------------------|----------------------------------------------------------------|---------------------------------|
| <input type="checkbox"/> Amendment / Response | | <input type="checkbox"/> Issue Fee | \$1280 |
| <input type="checkbox"/> Appeal Brief | \$320 | <input type="checkbox"/> Notice of Appeal | \$320 |
| <input type="checkbox"/> Assignment Recordation | \$40 | <input type="checkbox"/> Preliminary Amendment | |
| <input type="checkbox"/> Application Data Sheet | | <input type="checkbox"/> PTO - 1449 Form | |
| <input type="checkbox"/> Claim of Priority | | <input type="checkbox"/> Request for Certificate of Correction | |
| <input type="checkbox"/> Declaration - Missing Parts / | \$130 | <input type="checkbox"/> Request for Corrected Filing Receipt | |
| Missing Requirements | | <input type="checkbox"/> Response to Final Rejection | |
| <input type="checkbox"/> Disclosure No. <u> </u> | | <input type="checkbox"/> Supplemental Information | |
| <input type="checkbox"/> Division Check | | Disclosure Statement | |
| <input type="checkbox"/> Drawings | | <input type="checkbox"/> Late Fee (\$180) | <input type="checkbox"/> No Fee |
| <input type="checkbox"/> Information Disclosure Statement | | | |
| <input type="checkbox"/> Late Fee (\$180) | <input type="checkbox"/> No Fee | | |

☐ Extensions of Time

☐ 1st (\$110) ☐ 2nd (\$400) ☐ 3rd (\$920)

- | | | |
|-----------------------------------------------------------------------------------------|----------------------------------------------|-------|
| <input type="checkbox"/> Application (With Basle Fax - on U.S.
Originated Case Only) | <input type="checkbox"/> Provisional | \$160 |
| <input type="checkbox"/> PCT | <input type="checkbox"/> Petition to Convert | \$50 |

Fee \$ ☐ CIP ☐ Continuation ☐ Divisional ☐ Filed "A" (Old "R")

X Other Petition to Withdraw HOLDING OF ABANDONMENT

ATTORNEY: Bian Zhong DATE: 5, 10, 02
(SUC)

UNITED STATES PATENT & TRADEMARK OFFICE
Washington, D.C. 20231

REQUEST FOR PATENT FEE REFUND				
1 Date of Request: <u>11/06/08</u>		2 Serial/Patent # <u>09/525,158</u>		
3 Please refund the following fee(s):		4 PAPER NUMBER	5 DATE FILED	6 AMOUNT
	Filing			\$
	Amendment			\$
	Extension of Time			\$
	Notice of Appeal/Appeal			\$
X	Petition 1453	16	06/25/08	\$ 1,540.00
	Issue			\$
	Cert of Correction/Terminal Disc.			\$
	Maintenance			\$
	Assignment			\$
	Other			\$
7 TOTAL AMOUNT OF REFUND			\$ 1,540.00	
8 TO BE REFUNDED BY:				
10 REASON:		Treasury Check		
	Overpayment	X	Credit Deposit A/C #:	
X	Duplicate Payment	9	<div style="display: flex; justify-content: space-around; border: 1px solid black;"> 50--2965 </div>	
	No Fee Due (Explanation):			
fee was paid with initial petition 9/14/07				
11 REFUND REQUESTED BY:				
TYPED/PRINTED NAME: <u>Douglas I. Wood</u>		TITLE: <u>Senior Petitions Attorney</u>		
SIGNATURE: <u>/douglas wood/</u>		PHONE: <u>571-272-3231</u>		
OFFICE: <u>Office of Petitions</u>				
***** THIS SPACE RESERVED FOR FINANCE USE ONLY: *****				
APPROVED: <u><i>CKHOK</i></u>		DATE: <u>11/12/08</u>		

Instructions for completion of this form appear on the back. After completion, attach white and yellow copies to the official file and mail or hand-carry to:

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.